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ABSTRACT
Advanced coronary artery disease (CAD) is the most frequently observed long term
complication of cardiac transplantation. Studies report prevalence rates up to 70 per cent at
five years post-transplant. In addition to immunologically mediated factors, conventional
cardiovascular risk factors have been implicated in the development of CAD. The purpose of
this research project was to investigate the cardiovascular profile and dietary intake of cardiac
transplant recipients at twelve to twenty-four months post-transplant at St. Vincent's
Hospital, Sydney.
The study population consisted of 27 post-cardiac transplant patients. Data including body
weight, serum lipid levels, blood pressure and the presence of diabetes mellitus in the posttransplant period was retrospectively analysed from St. Vincent's Hospital records. Waist-tohip ratios (WHR) were measured at the time of participation in the study and compared to
recommendations. Each participant was also interviewed for approximately one hour to
obtain an extensive diet history.
Analysis of anthropometric data indicated that body weight increased progressively
throughout the post-transplant period. At twelve months post-transplant, 56 per cent of
recipients were classified as overweight and one third of these obese. Mean weight gain was
7.8 kg. Eighty eight per cent of the transplant population displayed WHR's larger than
desirable. Cholesterol levels showed a steady post-transplant increase which reached
statistical significance at three months post-transplant (p<0.01). Hypertension, as indicated
by a diastolic blood pressure >95 mmHg or the administration of anti-hypertensive
medications was present in 73 per cent of this population at 12 months post-operative.
However, none of the participants displayed persistent uncontrolled hypertension. Posttransplant diabetes mellitus was prevalent in 19 per cent of transplant recipients. An analysis
of dietary intake data indicated that 63 per cent of transplant recipients had a fat intake greater
vili

than recommended, with a mean 31.7 per cent contribution to energy. Sodium and saturated
fat intakes were also significantly greater than current healthy heart recommendations
(p<0.01; p<0.05).

The findings of this study suggest that cardiovascular risk factors are frequent in long term
cardiac transplant recipients. Biochemical indicators and body weight should therefore be
regularly monitored throughout the post-transplant period. Whilst more stringent efforts at
weight control including intensive dietary intervention and encouragement of exercise within
the first 12 months post-ttansplant, may be beneficial in improving cardiovascular profile and
possibly assist in the prevention of cardiovascular complications such as CAD.

2. Literature Review

1. INTRODUCTION
Cardiac transplant recipients are a high risk group for the development of long term
cardiovascular complications including coronary artery disease. The aetiology of this
disorder remains highly controversial, however conventional cardiovascular risk factors
including hyperlipidaemia, obesity, hypertension, diabetes mellitus and dietary intake
have been suggested to play a role.

Anecdotal evidence from the St. Vincent's Hospital cardiac transplant population
suggests that cardiovascular risk factors are prevalent in a large proportion of transplant
recipients. Information regarding the profile of these risk factors and the long term
dietary intake of this population, however, is largely unreported in Australia. This smdy
attempts to address these issues by determining the long term cardiovascular profile and
nutritional status of this group. In turn, this information will form the basis for an
evaluation of the effectiveness of current nutrition services at St. Vincent's Hospital,
Sydney.

1.1 Aim
The aim of this project is to investigate the cardiovascular profile and dietary intake of St.
Vincent's Hospital cardiac transplant patients at twelve to twenty-four months posttransplant.

1.2 Objectives
The objectives of this project include:

1.2.1 To record blood lipid levels in cardiac transplant recipients and determine changes
in lipid profile in the post-transplant period

1.4.2 To record body weight in cardiac transplant recipients and determine the pattern of
weight change in the post-transplant period

1.4.3 To determine the body fat distribution of cardiac transplant recipients in the posttransplant period

1.2.4 To determine what proportion of cardiac transplant recipients display diabetes
mellitus in the post-transplant period

1.2.5 To determine what proportion of cardiac transplant recipients display hypertension
in the post-transplant period

1.2.6 To describe the usual dietary intake of cardiac transplant recipients in the posttransplant period and compare with current dietary recommendations

1.3 Definition of Terms

Cardiomyopathy:
A disease of the muscle of the heart. Can be dilated, hypertrophic or restrictive in its
presentation. Can be idiopathic - of unknown cause or related to the outcome a variety of
factors (eg. alcohol) (Weatherall et al 1989)

Cardiovascular Risk Factors:
Factors which have been identified as increasing the risk of coronary heart disease.
Includes high blood pressure, obesity, elevated cholesterol, diabetes mellitus, diet,
smoking and physical inactivity (National Heart Foundation 1989).

Congestive Cardiac Failure:
A disorder where the heart fails to adequately pump blood throughout the body. The
result is circulatory congestion and sodium retention which leads to shortness of breath
and oedema (Rothenberg and Chapman 1994).

Coronary Artery Disease (CAD) :
A disorder whereby lipid filled plaques develop on the inner walls of the coronary arteries
narrowing the lumen and reducing blood flow to the heart.

Also known as

atherosclerosis (Rothenberg and Chapman 1994).

Hyperlipidaemia:
Elevated levels of lipids in the blood. These include cholesterol, lipoprotein subfractions
(low density lipoprotein, high density lipoprotein) and triglycerides.

Hypercholesterolaemia:
Serum cholesterol levels exceeding 5.5 mmol / Litre (National Heart Foundation 1989)

Hypertriglyceridaemia:
Serum triglyceride levels exceeding 1.8 mmol / Litre (Curtin University of Technology
1992)

Hypertension:
Blood pressure elevated above diastole 95mmHg and systole ISOmmHg (Stamler et al
1993). Although a variety of definitions are used by different researchers.

Immunosuppressants:
Medications which act to suppress normal immune responses. In heart transplant patients
these commonly include corticosteroids, cyclosporine and azathioprine (Reynolds 1989).

Ischaemic Heart Disease (IHD):
A disease whereby there is a decreased blood flow to the heart. Usually the result of
atherosclerosis (Rothenberg and Chapman 1994).

Myocarditis:
Inflammation of the myocardium (heart muscle). Can be caused by viral infections, or
bacteria, results in fatigue, dyspnoea and tachycardia (Weatherall et al 1989).

Orthotopic Heart / Cardiac Transplantation:
A medical procedure whereby the heart from a donor operatively replaces a recipients
own failed heart.

Peripartum Heart Disease:
Dilated cardiomyopathy with pregnancy acting as a facilitator (Weatherall et al 1989).

2.1 CORONARY ARTERY DISEASE IN CARDIAC
TRANSPLANTATION
Cardiac transplantation has become recognised as a successful treatment for end stage
heart failure. Each year over 100 orthotopic heart transplants are performed in Australia
and to date over 800 transplants have been completed among the four major transplant
centres. The major indications for cardiac transplantation include ischaemic heart disease,
idiopathic cardiomyopathy, myocarditis and congenital heart disease. Survival rates for
transplant recipients have improved significantly over the past two decades, reaching 86
per cent at one year and approximately 78 per cent at five years (Australian & New
Zealand Cardiothoracic Organ Transplant Registry 1994). Mortality during the first year
is related to operative complications, infection and rejection (Mann 1992). However, the
most frequently observed long term complication of cardiac transplantation is an
accelerated form of coronary artery disease (CAD) (Scott and Dark 1992).

The clinical presentation of post-transplant CAD often differs from conventional
atherosclerosis. It frequently develops in smaller coronary vessels, is concentric, diffuse
and characteristically occurs at a rapid rate without the development of a collateral blood
supply (Mullins et al 1992). Less commonly, transplant CAD may appear as a plaque
which is indistinguishable from conventional atherosclerosis (Schroeder et al 1992).
Transplant CAD is often clinically silent in its development, as a result of denervation
(Gao et al 1990). Mortality due to CAD is commonly the result of fatal myocardial
infarcts, congestive heart failure and cardiac arrhythmia's. In addition, graft failure as a
result of CAD is a frequent indication for re-transplantation (Schroeder et al 1992).

Prevalence rates for post-transplant CAD have been reported from two to 28 per cent at
one year post-transplant and up to 70 per cent at five years (Gao et al 1989, Narrod et al
1989, Mullins et al 1992). Survival rates appear to be a function of CAD advancement.
Mullins et al (1992) reported a 60 to 80 per cent survival rate three years after CAD

diagnosis. However, survival rates in more advanced CAD are much poorer. Three
year survival rates of 22 per cent have been reported for CAD affecting a single vessel
with greater than 40 per cent stenoses, whilst survival with triple vessel disease over the
same period is as low as 6 per cent (Keogh et al 1991).

A number of factors have been suggested to predispose the heart transplant recipient to
CAD, although the relative contribution of each has not been established. It has been
suggested that post-transplant CAD is an immunological mediated disease (Stovin et al
1991). It has been related to donor specific cytotoxic antibodies and cellular rejection.
Uretsky et al (1987) in studies on CAD, reported that transplant recipients with more than
two episodes of rejection within the first year post-transplant, had an increased risk of
developing CAD. However, these findings have not been consistently reported in the
literature (Stovin et al 1991).

Viral infections, notably cytomegalovirus (CMV) have been shown to correlate with the
development of post-transplant CAD (Stovin et al 1991). CMV has been reported in up
to 90 per cent of heart transplant recipients (Dummer 1990). It has been suggested that
CMV may be an initiator of atherosclerosis through its damaging influence on the
endothelium (Stovin et al 1991). In animal studies, the virus has been shown to increase
cholesterol incorporation into the arterial intima and alter the normal synthesis and
metabolism of cholesterol (Miller 1991). Studies on the influence of CMV have produced
mixed results with some reporting a relationship (Stovin et al 1991) and others finding no
significant influence on CAD development (Sharpies et al 1991).

Donor and recipient characteristics have both been suggested to play a role in posttransplant CAD. A number of studies have indicated that CAD occurs more commonly in
recipients of hearts from older donors (Sharpies et al 1991). Older recipients themselves,
notably over the age of 50 years, may also be at greater risk of post-transplant CAD. The
sex of both donor and recipient may additionally influence CAD development (Sharpies et

al 1991), as might donor ischaemic time (Miller 1991). Further, certain tissue type
mismatches may be predictive of CAD development (Stovin et al 1991).

There is some evidence that pre-operative diagnosis may be related to CAD development.
Transplant recipients with ischaemic heart disease as the initial cause of heart failure, have
been shown in some studies to be at an increased risk of developing this accelerated form
of CAD (Sharpies et al 1991). In comparison recipients with a diagnosed cardiovascular
disease without atherosclerotic involvement, such as a cardiomyopathy or valvular
disease may be at lower risk. Again, this is controversial in the literature.

A relationship between immunosuppressive medications including cyclosporine and
corticosteroids and CAD has been suggested. It is thought that prolonged treatment with
these medications may directly damage graft vessels (Dummer 1990). Indirect effects
such as hyperlipidaemia, hypertension and glucose intolerance have also been
demonstrated.

Conventional cardiovascular risk factors including hyperlipidaema, diabetes mellitus,
obesity and diet have also been implicated in this disorder. Due to the multi-factorial
nature of post-transplant CAD however, the role of these risk factors has not been
delineated. Eich et al (1990) proposed that the combined effect of endothelial damage and
associated risk factors may play a key role in post-transplant CAD. In this model,
immunosuppressive medications, immune responses, and viral infections combined with
diabetes mellitus and dyslipidaemia result in damage to the endothelium, platelet
aggregation, intimal smooth muscle proliferation and consequent CAD (refer to Figure
one). The aetiology, significance and role of these conventional risk factors in post
transplant CAD will be reviewed in each of the chapters to follow.
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Figure 2.1.1 Predisposing factors to the development of CAD in cardiac
transplant recipients (Adapted from Eich et al (1990))

2.2 HYPERLIPIDAEMIA
2.2.1. Hyperlipidaemia in Coronary Heart Disease
Raised plasma lipids have been clearly established as a strong and independent risk factor
for the development of coronary heart disease in the general population.
Hyperlipidaemia, which includes elevations in total cholesterol, cholesterol sub-fractions
and triglyceride levels, increases cardiovascular risk through its influence on the
development of atherosclerosis (Gotto et al 1990).

In the general population, the risk of heart disease begins to increase at total plasma
cholesterol levels above 3.9 mmol/L. The most considerable risk, however, occurs at
cholesterol levels in excess of 5.2 mmol/L (Keogh 1987). The low density lipoprotein
(LDL) sub-fraction of cholesterol poses a significantly increased risk as a result of its
atherogenicity. High density lipoprotein (HDL) cholesterol on the other hand has been
shown to have a protective effect on cardiovascular health (Romm et al 1991). Further,
plasma triglycerides have been identified as a risk factor for CHD. However, this risk is
thought to be influenced by the association of hypertriglyceridaemia with low HDL
cholesterol, obesity and insulin resistance. It appears that elevated triglycerides pose
cardiovascular risk when HDL cholesterol is depressed in the presence of elevated total
cholesterol (Castelli 1986).

The role of hyperlipidaemia in coronary heart disease has been consistently reported in
both epidemiological and clinical studies. The Multiple Risk Factor Intervention Trial, a
randomised primary prevention study, for example, provided epidemiological data to
suggest that mortality from heart disease was strongly associated with serum cholesterol
levels (Multiple Risk Factor Intervention Trial Research Group 1982). Similarly, other
studies such as those from Framingham and the Lipid Research Clinics have reported

comparable evidence for the adverse cardiovascular consequences of hyperlipidaemia
(Kannel et al 1971; Lipid Research Clinics Program 1984).

2.2.2 Cardiac Transplant Hyperlipidaemia
Considering the evidence supporting a link between elevated blood lipids and heart
disease, it is possible that hyperlipidaemia plays a role in the establishment of posttransplant CAD. Studies by Eich et al (1991) support this hypothesis. In a retrospective
review of 38 heart transplant recipients, they found that hypercholesterolaemia at six
months post-transplant was a strong predictor of subsequent CAD. Similarly, Barbir et
al (1991), in comparing cumulative cardiovascular risk in patients with and without
hyperlipidaemia, indicated that the probability of CAD was greater in transplant
recipients with cholesterol above 5.8 mmol/L. In the same study, the incidence of CAD
was greater in patients with triglyceride levels above 1.4 mmol/L. Another study by
Winters et al (1990), also confirmed a significant relationship. In an analysis of the
extent of coronary arteriopathy in transplant recipients, they reported that patients with
higher mean cholesterol and triglyceride levels had a significantly more luminal
narrowing. These results and those from a number of other studies clearly suggest a role
for hyperlipidaemia in the evolution of CAD. However, some researchers have
suggested that hyperlipidaemia occurring in combination with other factors such as
cytotoxic antibodies and HLA mismatch is necessary for the development of CAD in this
setting (Ballantyne et al 1987).

Hyperlipidaemia is frequently demonstrated in both renal and heart transplant recipients.
The incidence in heart transplant patients has been reported to vary from 33 to 83 per cent
for hypercholesterolaemia (Keogh et al 1988; Rudas et al 1990). Hypertriglyceridaemia
has been found in up to 10 per cent of the same population (Keogh et al 1988). There is
considerable variability in the literature regarding the predominate lipid abnormalities.
Grady and Herold (1988) found that elevations in post-transplant triglyceride and total
cholesterol were most frequent. They reported an increase in mean triglyceride

concentrations from 3.5 to 5.7 mmol/L. Whilst total cholesterol increased from 4.6 to
6.8 mmol/L. Keogh et al (1988) confirmed similar increases in total cholesterol,
however, changes in triglycerides were less frequent. Elevations in lipid sub-fractions
have also been reported. Becker et al (1988) in a study of recipients from a number of
heart transplant centres, discovered elevations in LDL and HDL cholesterol as well as
total cholesterol and triglyceride levels. Thirty eight per cent of these patients were above
the 90th percentile for total cholesterol when compared to a reference population,
indicating that hyperlipidaemia is a particular concern for this population.

In heart transplant recipients, hyperlipidaemia appears to occur as a progressive increase
in lipid levels within the first twelve months post-transplant. Although this pattern has
shown variation in different studies. Keogh et al (1988) in a study on twenty-two heart
transplant recipients reported mean serum cholesterol increases which peaked at 3 months
post-transplant.

At twelve months post-transplant a significant degree of

hypercholesterolaemia ( > 6.5 mmol/L) was found in nine of the transplant patients.
Mean serum triglyceride levels were also found to be higher in the post-transplant period.
Similarly, Ballantyne et al (1992) in a larger study, reported elevated total cholesterol and
triglycerides in the first three months following transplantation.

They found no

significant changes in lipid profile after this time. The findings of Lake et al (1993)
however, propose a different pattern of hyperlipidaemia. In a prospective study of 89
transplant recipients, they noted increases in total cholesterol, LDL cholesterol and blood
triglycerides at 12 months, which remained elevated at 24 months post-transplant. Earlier
post-operative elevations in lipids have also been suggested by some researchers.
Stamler et al (1988), for example, reported significant elevations in both LDL and total
cholesterol at 2 weeks post-transplant. At 3 months, these levels peaked and remained
elevated for 12 months post-operatively. In the same study triglyceride and HDL
elevations were noted at 3 months post-transplant but did not reach statistical
significance.
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Overall, the majority of studies report evidence of hyperlipidaemia in cardiac transplant
recipients. Although inconsistencies in the literature are evident, it is important to
recognise that there are a number of potential sources of inaccuracy in determining blood
lipid levels. In the pre-transplant period, patients are susceptible to cardiac cachexia, liver
dysfunction and in some cases myocardial infarcts, all of which are known to modify
serum lipids. Similarly, blood samples taken immediately post-operatively may not
reflect true lipid values due to the metabolic stresses of major surgery (Rosenson 1993;
Ballantyne et al 1987). Hence data which suggests changes in lipid profiles from pre to
post-transplant must be interpreted with care. Further, drawing comparisons between
studies is difficult with different variables, for example, medication protocols potentially
affecting lipid levels.

The mechanism by which hyperlipidaemia develops in the post-transplant period is not
clear, but immunosuppressive treatment has been implicated as a major cause. The
negative effects of corticosteroids on lipid levels have been widely reported in patients
receiving long-term immunosuppression for inflammatory and connective tissue
disorders (Bagdale et al 1970; El-Shaboury and Hayes 1973). In a healthy population,
the steroid prednisone has been shown to induce elevations in plasma total cholesterol,
LDL cholesterol and HDL cholesterol within 48 hours of administration (Zimmerman et
al 1984). More recently similar findings have been reported in heart transplant recipients.
The most convincing evidence comes from studies which suggest that cholesterol levels
decrease when patients are tapered off steroids. For example, Renuld et al (1989) found
that withdrawal of the corticosteroid, prednisone was associated with cholesterol levels of
21 to 26 per cent lower than patients maintained on prednisone therapy.

Similar,

although less dramatic findings have been reported in other studies (Lake et al 1993).
The influence of corticosteroids on blood lipids is thought to occur as a result of
decreased post-heparin lipolytic activity, glucose intolerance and increased accumulation
of dietary fat (Elasser and von Eickstedt 1992). Although these findings have not been
demonstrated in all studies of hpid elevations in transplant patients (Superko et al 1990).

The powerful immunosuppressant, cyclosporine has also been demonstrated to adversely
affect lipid profile. Increased levels of total cholesterol and triglycerides have been
reported in both renal and heart transplant recipients with cyclosporine administration
(Harris et al 1986; Superko et al 1990; Winters et al 1990). Total cholesterol elevations
are thought to be the result of increased LDL cholesterol. Whilst cyclosporine has been
inversely related to lipoprotein lipase and hence elevated blood triglycerides (Superko et
al 1990). Several researchers have reported an adverse effect of cyclosporine on lipid
levels. Stamler et al (1988) demonstrated that changes in lipid levels in patients receiving
cyclosporine differed from that with other immunosuppressive regimens, an effect which
they related to the hepatotoxic effects of this drug. However, failure to control for other
variables, including diet and medication makes the significance of these findings
questionable. More convincing evidence comes from a trials undertaken by Ballantyne et
al (1989). In comparing the lipid profile of patients treated with cyclosporine and those
receiving a placebo, they reported significant increases of 21 per cent in total cholesterol
and 31 per cent in LDL cholesterol. In comparison, Becker et al (1988), found that the
influence of cyclosporine on lipid levels was insignificant. However, they reported that
cumulative prednisone exposure was the strongest predictor of unfavourable lipid
profiles. Other studies have suggested that cyclosporine therapy enhances the effect of
corticosteroids on serum lipids (Johnson 1992). However, there is no clear consensus in
the literature regarding the exact role that cyclosporine plays in the establishment of
hyperUpidaemia.
Obesity following heart transplantation is a possible contributing factor to the
development of lipid abnormalities. Excessive accumulation of body fat, as prevalent in
the transplant population has been associated with poor lipid profiles (Bonora et al 1991).
A possible role in the development of post-transplant hyperlipidaemia is therefore
evident. Studies by Keogh et al (1988) support this suggestion. In research on
hyperlipidaemia they demonstrated a correlation between body weight and serum lipid
levels. It was suggested that 81 per cent of the variation in total cholesterol and 72 per

cent of that in triglycerides could be explained by increases in body weight. Similariy,
Rudas et al (1990) reported that the presence of obesity at one year post-transplant was
significantly associated with hyperlipidaemia. Studies on renal transplant recipients have
produced similar findings. Vathsala et al (1989) for example, demonstrated that
hypertriglyceridaemia in renal transplanted patients was one of several factors
aetiologically linked to obesity. Considering the initial cause of weight gain is often
corticosteroid related, the development of lipid abnormities via obesity may therefore be a
further adverse consequence of steroid administration.

Initial diagnosis and pre-transplant hyperlipidaemia have also been suggested as
predictors of lipid profiles following cardiac transplantation. Studies have found that
patients with a history of lipid abnormalities show higher post-operative lipid values.
Lake et al (1993) reported evidence of this at both 12 and 24 months post-transplant.
These findings agree with those of Rudas et al (1990) which suggest that hyperlipidaemia
in the post-transplant period results from the normalisation of cardiac function.
Elsewhere, a pre-operative diagnosis of coronary artery disease (which is associated with
lipid abnormalities) has been reported as being predictive of post-transplant
hyperlipidaemia (Rudas et al 1990; Keogh et al 1988; Taylor et al 1989). Although there
is considerable support for this relationship it has not been consistently reported in the
literature.

As a modifiable cardiovascular risk factor, prevention or effective treatment of
hyperlipidaemia would clearly be of some benefit in CAD risk modification. Initial
attempts to control lipid elevation through pharmacological lipid lowering agents were
largely unsuccessful (Keogh 1987). These medications resulted in a number of adverse
side effects and demonstrated little benefit on improving lipid profiles. More recently
however, newer treatment protocols have demonstrated improved outcomes. However,
potential side effects and drug interactions remain important considerations for these

patients (Ballantyne et al 1989). The efficacy of diet and lifestyle modifications in this
setting have been controversial. These will be discussed further in chapters to follow.
In summary, hyperlipidaemia is a significant complication of heart transplantation.
Unlike conventional hyperlipidaemia, the aetiology of this disorder has not been
established. A multitude of factors have been implicated, yet none has been consistently
demonstrated. It is possible that a combination of immunosuppressive medication,
obesity, pre-transplant lipid status and pre-operative diagnosis contribute to lipid
abnormalities in this setting. Further, renal insufficiency, diabetes, anti-hypertensive
medications, recipient age, dietary intake and ethanol may exacerbate changes in lipid
profile (Lake et al 1993). Clearly, an effective means of preventing lipid abnormalities
would be beneficial to the cardiovascular profile of these patients and possibly alter the
pathway for CAD development

2.3 OBESITY
2.3.1 Obesity and Coronary Heart Disease
Obesity, the excessive accumulation of body fat has been strongly correlated with the
development of coronary heart disease. Obese individuals have been reported to have a
an increased risk of heart disease, which is associated with considerable morbidity and
mortality (Noppa et al 1980). The role of obesity as a cardiovascular risk factor has been
shown to be both independent and via the influence on other risk factors (Hubert et al
1983).

The health implications of obesity have been widely reported (Larrson et al 1981; Garrow
1991).

Large controlled studies have demonstrated a variety of metabolic and

cardiovascular consequences in obese populations. Insulin resistance is one such factor
which has been related to the development of diabetes mellitus and poor lipid profiles,
hence the risk of coronary heart disease (Hartz et al 1983; Felber 1992). Hypertension
has also be reported as a significant complication which may have initiating effects on the
process of atherosclerosis (Stamler et al 1978). In addition, abnormalities in serum
cholesterol and triglycerides have been demonstrated to occur in obesity (Forde et al
1986; Bonora et al 1991). Further, obesity has been shown to increase cardiac output via
its influence on blood volume, stroke volume and left ventricular end-diastolic volume.
Hence the consequences may be left ventricular hypertrophy and cardiac failure (Hagan et
al 1990). As a result, obesity has negative implications for cardiovascular profile and thus
the risk of coronary heart disease.

2.3.2. Body Fat Distribution and Coronary Heart Disease
There is evidence that the distribution of body fat may pose additional cardiovascular
risk. Upper body obesity (android) has been more strongly associated with the myriad of
metabolic aberrations including hyperinsulinaemia, diabetes mellitus, hypertension and

dyslipidaemia (Egger 1992). In contrast obesity of the lower body (gynoid) has been
shown to have fewer health complications (Despres et al 1990). As a result, the android
pattern of obesity has been associated with an increased risk of coronary heart disease
and consequent morbidity and mortality (Donahue et al 1987; Ducimetiere and Richard
1989; Hartz et al 1990; Rimm et al 1995).
The metabolic consequences of increased adiposity in the upper body region are related to
the presence of visceral or intra-abdominal fat (Zamboni et al 1994). As opposed to
subcutaneous upper body fat, that of the intra-abdominal region lies deeper within the
abdominal cavity and is more metabolically active (Calvert 1991). Consequentially, it
influences insulin, glucose, fatty acid and lipoprotein metabolism (Despres et al 1990).
Although the mechanisms by which these disturbances occur are not completely
understood it is evident that the android pattern of obesity has multiple cardiovascular
implications. This is supported by recent research which has described an independent
role for central obesity in the development of cardiovascular disease (Hartz et al 1990).
However, the fact that abdominal fat increases with age and differs amongst the sexes
makes the independent contribution of this pattern of body shape in the absence of
obesity per se, controversial. Some researchers have suggested that increased abdominal
fat, as indicated by anthropometric measures, enhances the detrimental effects of obesity
on metabolism (Depres 1992). Thus an increased body weight in conjunction with a
large abdominal region of adiposity may be predictive of cardiovascular risk.
2.3.3 Obesity and Cardiac Transplantation
Excessive weight gain is a frequently observed complication of heart transplantation
which has been identified as a prognostic factor in the progression of CAD (Poindexter et
al 1990). Prior to transplantation patients may be underweight as a result of
compromised cardiac function, suppressed appetite and catabolism. Following
transplantation however, significant weight gain often resulting in obesity has been
documented in a large proportion of patients (Robert et al 1990).

Obesity is thought to influence the risk of transplant CAD through similar metabolic and
cardiovascular pathways as non-transplant coronary heart disease. Winters et al (1990)
in a study of failed human heart allografts reported that body mass index was, of forty
risk factors studied, the single most predictive in the development of coronary
arteriopathy. However, this data is not consistently supported in the literature. Other
researchers have failed to demonstrate obesity as a primary risk factor for the
development of CAD, hypertension or hyperlipidaemia, indicating that other factors may
play a role (Poindexter et al 1990).
The most frequently demonstrated pattern of weight gain appears to be a steady increase
throughout the post-transplant period. Baker et al (1992) demonstrated that changes from
baseline weight in transplant recipients were significant at bi-monthly post-transplant
intervals, with significant increases between each measure. In another study, ideal body
weight increased from 102 per cent at surgery to 113 per cent at one year post-transplant
(Poindexter et al 1990). Twenty seven per cent of the patients in this study were
classified as obese. Similarly, Grady et al (1990) reported significant weight increases in
the post-transplant population which remained elevated over the first three post-operative
years. A comparable pattern has been shown in other organ transplant populations
(Gardiner 1993).
Corticosteroid administration has been implicated as the major cause of weight gain
following transplantation. Heart transplant recipients are prescribed corticosteroids as a
means of suppressing immune responses which may initiate rejection of the donor heart
(Reynolds 1989). Long term patients are usually sustained on low "maintenance" doses,
whilst dosage is increased in periods of acute rejection. The means by which
corticosteroids induce changes in body weight can be attributed to both the stimulation of
appetite and metabolic effects as a result of increased gluconeogenesis (Elasser and von
Eickstedt 1992). An additional side effect, Cushings Syndrome, whereby the function
of the adrenal cortex is suppressed, is related to the development of obesity, facial

rounding and oedema (Garrow 1985). Early studies on the side effects of corticosteroids
demonstrated that muscle wasting and increased fat stores were commonly exhibited
(Schnieder 1977). Evidence of fat redistribution from peripheral to truncal regions has
also been suggested (Melby 1974). Hence the profile of weight changes appear to be
gain in total body fat (and resultant weight) as well as notable increases in adipose in the
abdominal region as a result of corticosteroid treatment. This pattern appears to be
similar to that which poses the greatest cardiovascular risk.

Studies on corticosteroid-free immunosuppressed patients support the earlier evidence for
a role of steroid therapy in weight gain. Hagan et al (1990) in a retrospective comparison
of steroid versus non-steroid treated heart transplant recipients reported a mean weight
difference of 4.2 kilograms between the two groups, with those receiving steroids being
of a significantly greater weight.

It is notable however, that the researchers did not

control for the influence of dietary intake, hence weight changes may not be attributable
solely to steroid therapy. Another study by Lake et al (1993) found similar weight
increases with steroid administration, however these did not reach statistical significance.
Interestingly, it was also demonstrated in both of the above mentioned studies, that those
who were obese prior to undergoing transplantation gained significantly more weight in
the post-transplant period. Changes in body fat distribution were not examined by these
investigators. The findings of the available research to date suggest a probable role for
corticosteroid induced weight gain. Further reseai'ch would be beneficial to discriminate
contributing factors.

Despite anecdotal evidence for changes in body composition in heart transplant recipients,
supporting evidence from the literature is scarce. One study undertaken by Kavanaugh et
al (1989) using skinfold measurements assessed 36 heart transplant patients at a mean
time of seven months post-transplant. They described changes in body composition as
reductions in fat-free mass, body mass index and percentage body fat. These findings
differ from the proposed body composition changes suggested by other researchers.

However only six of the subjects were receiving steroid therapy during the study period,
the results therefore are not comparable with corticosteroid immunosuppressed transplant
populations. More recently the body composition of transplant recipients maintained on
steroid therapy have been assessed using hydrostatic weighing. Keteyian et al (1992) in
a study on 24 patients at a mean 21 months post-transplant noted increases in body
weight and percentage body fat which reached statistical significance. The mean weight
gain for this group of patients was 9.7 kilograms and body composition was reported to
be 34 per cent fat, ranking participants on the 15th percentile for body fat when compared
to the general population. The prednisone dose and length of post-operative period were
inversely related although not additive in their effect on body density. The weight
changes indicated in this study are comparable with the 12 kilogram increase at 24
months post-transplant reported by Poindexter et al (1990). However, it is considerably
greater than the four kilograms weight gain demonstrated in another study (Keogh et al
1988). These inconsistencies are possibly attributed to the differing periods at which
patients were assessed or variations in medication protocols.

In heart transplant recipients, evidence for increased abdominal or android fat distribution
remains largely undocumented. In other patients populations treated with steroids,
however the proposed increased abdominal distribution of body fat has been questioned.
Horber et al (1986) using computed tomography found that patients on long term
glucocorticoids exhibited normal or even increased mid thigh fat areas as well as
increased central fat stores. This led the researchers to conclude that the traditional
concept of fat redistribution from the peripheral to central regions as a result of steroid
treatment requires revision. It is still notable however, that both intra-abdominal and
subcutaneous central adiposity, did in fact increase and muscle wasting as originally
described was evident. Therefore although a typical android pattern may not be
manifested in these patients, the metabolic implications of increased abdominal fat stores
are still likely to result. Further evidence specifically related to heart transplant recipients
is needed to clarify these issues.

Apart from corticosteroids, a number of other factors have been suggested to predispose
transplant recipient to obesity. Improvements in quality of life for example, may play a
major role in post-transplant weight gain. Patients frequently exhibit enhanced feelings
of well being and thus are able to resume an adequate oral diet. In the long term, this
may result in excess in caloric intake. In addition improved gastrointestinal absorption of
nutrients in post-transplant patients and may impact upon body weight (Keogh 1987).
Further, factors such as physical inactivity and fluid retention may contribute to weight
changes (Grady and Herold 1988).

In summary, it is evident that overweight and obesity are significant complications of
cardiac transplantation. The underlying cause of this appears to be multifactorial. In the
long term transplant recipients, maintaining a healthy weight is likely have desirable
consequences on lipid profiles, blood pressure, glucose tolerance and cardiac function
which may have positive impHcations for CAD prevention.

2.4 DIABETES MELLITUS
2.4.1. Diabetes and Coronary Heart Disease
Diabetes mellitus is a disorder characterised by a deficiency or reduced sensitivity of
insulin with resultant blood glucose elevations and metabolic aberrations. In the long
term, both insulin dependant and non-insulin dependant individuals are at increased risk
of developing multiple chronic complications including atherosclerosis (McDonald and
Roberts 1990). Consequently, coronary heart disease affects a large proportion of
individuals with diabetes and is a major cause of morbidity and mortality in this
population (Zimmet and King 1986; Moss et al 1991; De Stafano 1993).

The development of atherosclerosis and the resultant cardiovascular complications have
been attributed to the interaction of several key factors. Lipid abnormalities including
elevations in total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels
are extensively demonstrated in this population and are thought to result from alterations
in lipoprotein metabolism (Briones et al 1984; Reaven 1987). Plasma lipids have been
shown to vary depending on glycaemic control, body fat composition and the
development of diabetes related complications such as nephropathy (Dunn 1990).
Diabetes has been related to hypertension, which may induce endothelial damage thus
atherosclerosis. There is also evidence of hyperinsulinaemia playing a role in the
atherosclerotic process through its influence on lipid synthesis and deposition (Skinner
1993). Other contributing factors include obesity and blood platelet malfunctioning both
of which are prevalent in diabetes mellitus (Felber 1992; MacRury et al 1993).

Large controlled studies have shown that the occurrence of coronary heart disease is
increased in diabetes mellitus. The Framingham Study demonstrated that the incidence
of cardiovascular complications was doubled in diabetic males and tripled in diabetic
females when compared to control subjects (Kannel and McGee 1979). More recently.

other investigators have reported that blood glucose concentrations are correlated with
cardiovascular risk (Welin et al 1992). Numerous other studies have confirmed such a
relationship between diabetes mellitus and coronary heart disease (De Stafano et al 1993;
Stamler et al 1984).

2.4.2 Diabetes and Cardiac Transplantation
Diabetes Mellitus has been demonstrated in various studies on post-cardiac transplant
recipients (Ladowski et al 1989; Rhenman et al 1988). There are three possible scenarios
which may explain the development of diabetes in this setting. Firstly, recipients may
exhibit pre-existing insulin or non-insulin dependant diabetes (Rheman et al 1988).
Alternatively, post-transplant obesity may initiate the glucose intolerance and
hyperinsulinaemia characteristic of diabetes.

A final possibility is the use of

immunosuppressant medications which may induce metabolic changes and lead to the
development diabetes mellitus (Elasser and von Eickstedt 1992). It is also plausible that a
combination of these factors results in the post-transplant development of this disorder.

Although diabetes mellitus has been established as a risk factor for the coronary heart
disease seen in the general population, evidence for a role in post-transplant CAD has not
been widely reported. A study by Ladowski et al (1989) attempted to determine the
impact of post-transplant diabetes mellitus on survival following heart transplantation.
They reported a three year survival rate of 75 per cent in transplant recipients with
diabetes which compares favourably with survival for the non-diabetic transplant
population. Similar findings have been reported by other researchers (Rhenman et al
1988). In the same study, Ladowski et al (1989) failed to demonstrate any difference in
the development of CAD in patients with diabetes when compared with the total
transplant population. Eich et al (1991) additionally failed to find any differences in the
incidence of CAD between patients with and without diabetes at six months posttransplant. However, the small sample size and demonstrated low incidence of CAD in
the total population at six months post-transplant make the validity of these findings

questionable. Overall, the present lack of research makes it difficult to either support or
dispute the role of post-transplant diabetes mellitus in CAD. However, it is still
important to recognise that diabetes in the post-transplant period may have adverse
consequences for the development of other risk factors, such as hyperlipidaemia (Taylor
etal 1989).
Diabetes mellitus has been reported to affect from 8 to 14 per cent of the cardiac
transplant population (Utresky et al 1987; Ladowski et al 1989). This is comparable with
the prevalence rates demonstrated in other organ transplant populations (Boudreaux et al
1987). However, it is possible in heart transplant patients that glucose intolerance and
hyperinsulinaemia occur frequently without the development of diabetes per se. This
suggestion is supported by Kemna et al (1994) who reported that male heart transplant
recipients had significantly higher plasma glucose and insulin concentrations in response
to an oral glucose tolerance test than matched controls. A large proportion of transplant
recipients may therefore be at high risk of developing this disorder.
Corticosteroid administration is the most widely reported aetiological factor in the
development of diabetes following cardiac transplantation. The term steroid diabetes has
been used to describe the effects of this immunosuppressant on carbohydrate metabolism
and thus blood glucose levels. Corticosteroids have been shown to enhance
gluconeogenesis, with resultant increases in blood glucose levels of up to 20 per cent. In
addition, both tolerance to glucose and insulin sensitivity generally decrease. Pancreatic
function however, is not affected by steroid administration and ketosis does not
characteristically develop. The result is a dose dependant steroid induced diabetes
mellitus distinguished by a low insulin sensitivity and renal glucose threshold (Elasser
and von Eickstedt 1992). Studies in recipients of renal transplants have demonstrated the
existence of a relationship between steroid therapy and the development of diabetes
mellitus (Friedman et al 1985; Boudreaux et al 1987). In contrast, the few studies on

heart transplant patients to date have failed to find this effect, suggesting that other factors
may play a role in this disorder (Ladowski et al 1989).

The immunosuppressant cyclosporine may be additional factor which contributes to the
development of post-transplant diabetes mellitus. Animal studies offer support for this
hypothesis. Experiments on rats have demonstrated that cyclosporine has the potential to
impair glucose tolerance, initiate blood glucose elevations and adversely affect pancreatic
islet function (Hahn et al 1986). Thus a cyclosporine induced diabetes mellitus may
result. The animal model however, is not strongly supported in studies on human
transplant populations. Ladowski et al (1989) failed to find any relationship between
cyclosporine dosage and the development of diabetes in heart transplant recipients.
Whilst Harris et al (1986) reported similar findings in recipients of renal transplants.
Further, Boudreaux et al (1987) indicated that cyclosporine combined with other
immunosuppressive medications and recipient characteristics, such as age, contributed to
the development of diabetes mellitus following renal transplantation. Again, the scarcity
of evidence in the literature, particularly with the heart transplant population, make
conclusions regarding cyclosporine and post-transplant diabetes, controversial.

Studies reporting on other factors which may predispose heart transplant recipients to
diabetes mellitus are limited. Obesity is one such factor which is known to enhance
glucose intolerance, yet its role in post-transplant diabetes mellitus has not been
elucidated. One study by Boudreaux et al (1987) on renal transplant recipients reported
that the incidence of post-transplant diabetes mellitus was greater in patients weighing
over 70 kilograms. Similar evidence in the heart transplant population has not been
reported in the literature. Other factors potentially influencing the development of
diabetes, such as age and sex have also been largely ignored in the literature to date.

In summary, although post-transplant diabetes mellitus has not been demonstrated to
affect CAD risk as such, strong evidence from studies in the non-transplant population

clearly suggest that it is a potential contributing factor. As a result, efforts to reduce the
occurrence of this disorder and enhance glycaemic control may be beneficial to the long
term cardiovascular profile of transplant recipients. Such attempts would be improved
with further research into initiating factors in the development of post-transplant diabetes
mellitus.

2.5 HYPERTENSION
2.5.1 Hypertension in Coronary Heart Disease
Hypertension has been well established as a major risk factor for coronary heart disease
which affects a large proportion of the Australian population (National Heart Foundation
1989).

A diastolic and a systolic blood pressure exceeding 95 and 150 mmHg

respectively characterise this disorder which has been shown to increase the risk of
coronary heart disease by up to 40 per cent (Stamler et al 1993).

The cardiovascular effects of long term elevations in blood pressure are significant.
Hypertension has been shown to accelerate the development of atherosclerosis through its
damaging effects on the endothelium (Weber 1994). Uncontrolled blood pressure also
increases the workload of the heart and may contribute to cardiac failure (Skinner 1993).
In addition, hypertension frequently co-exists with other risk factors including
hyperlipidaemia, obesity and diabetes mellitus (Hansson 1992). Thus the risk of heart
disease is further increased.

Multiple long term studies have documented hypertension as a cardiovascular risk factor.
The Multiple Risk Factor Intervention Trial demonstrated that the relationship between
blood pressure and coronary heart disease was continuous, graded, strong and
independent of other risk factors (Neaton and Wentworth 1992). In the same study,
hypertension was estimated to be responsible for 49 per cent of deaths from heart
disease. An earlier study reported that the risk of mortality from heart disease was 1.6
times higher in males with a systolic blood pressure above 130 mmHg (Paffenberger et al
1978). A number of more recent published reports also document the significant
relationship of blood pressure elevations to coronary heart disease risk (Reed et al 1987;
Kannel 1990).

2.5.2 Hypertension following Cardiac Transplantation
In heart transplant recipients, hypertension is the most frequently observed of all
conventional cardiovascular risk factors. The role of this disorder in the CAD seen in
heart transplant recipients however, is not clear. Some studies have failed to demonstrate
any correlation between the presence of this anomaly and the subsequent development of
post-transplant CAD. Eich et al (1991) for example, in a study of 38 heart transplant
recipients reported that the relationship between hypertension and CAD was insignificant
at three years post-transplant. However, the small sample size used in this study may not
accurately demonstrate the true implications of uncontrolled hypertension. In contrast,
there is some evidence to suggest that hypertension may be a contributing factor to the
genesis of post-transplant CAD. Radovancevic et al (1990) confirmed that post-operative
arterial hypertension correlated significantly with the onset of CAD. Whilst, Winters et al
(1990) reported that a diastolic blood pressure above 90 mmHg when combined with
other risk factors had a cumulative influence on arterial lumen narrowing. This effect
however, did not occur independently. In addition to these findings, Shapiro et al (1990)
have suggested that blood pressure elevations are detrimental to the integrity of the
transplanted organ and contribute to considerable morbidity in the post-transplant
population. Although the evidence to date is limited, it is possible therefore, that
adequate blood pressure control may be of some assistance in the prevention of CAD
following cardiac transplantation.

Blood pressure elevations are a frequent occurrence following orthotopic heart
transplantation. The exact prevalence is difficult to determine due to the lack of available
data, the small sample size and varying definitions of hypertension used in the available
studies. However, blood pressure elevations have been demonstrated in up to 90 per
cent of cardiac transplant patients (Renuld et al 1989). The time course for the
development of this disorder shows variation in the literature. Olivari et al (1989) for
example, suggested that, at two weeks following transplantation 68 per cent of patients
were hypertensive, whilst at six months the prevalence was 92 per cent. It is important to

recognise however, that the investigators defined hypertension as a blood pressure above
140 / 90 mmHg, a level below the currently accepted definition of hypertension.
Ozdogan et al (1990) on the other hand reported that the probability of hypertension
(blood pressure > 150/95 mmHg) was 52 per cent at one year, 67 per cent at two years
and 73 per cent at three years, indicating that this disorder increases progressively with
time. In addition, Shapiro et al (1990) demonstrated that the mean initial onset occurred
at 50 days post-operative and ranged from one week to six months following
transplantation, suggesting that the development of hypertension is highly variable
amongst individuals following heart transplantation.

A multitude of factors are thought to impact upon the development of hypertension in
transplant recipients. Physiological changes following transplantation are thought to play
a role. Denervation, which occurs as a consequence of transplanting the human heart
has been shown in some studies to contribute to this problem via the loss of afferent
receptors within the heart which influence blood pressure (Shapiro et al 1990). Postoperative volume changes are thought to promote immediate post-transplant
hypertension. However, this does not explain the long-term existence of blood pressure
elevations. An alternative explanation which has been offered is the increased peripheral
resistance noted in heart failure, persisting in the presence of a transplanted heart (Shapiro
et al 1990).

In addition to physiological changes, immunosuppressive protocols may also be
inductive of hypertension. Cyclosporine is thought to be the major culprit in this
process. The mechanism by which this immunosuppressant increases blood pressure is
controversial. Regardless of this, there is little dispute that it plays a significant role in
hypertension development. The nephrotoxicity of cyclosporine is well documented
(Myers et al 1984; Martin et al 1987), thus the effects on renin and angiotensin activity
make a likely contribution to hypertension (Shapiro et al 1990). This effect however, has
been disputed in the literature, with some researchers reporting the absence of major

abnormalities in the activity of these enzymes with cyclosporine administration (Bellet et
al 1985). Furthermore, some studies have failed to find any association between
cyclosporine dose and blood pressure, indicating that nephrotoxicity may be unrelated to
this condition (Ozdogan et al 1990). An alternative explanation for the effects of
cyclosporine come from animal studies which suggest that this immunosuppressant is a
direct vasoconstrictor, thus a potential blood pressure elevator (Rego et al 1988).
Although the mechanisms by which cyclosporine affects blood pressure remain unclear,
it is evident that it plays a significant role in post-transplant hypertension.

The finding that hypertension also occurs in transplant patients not receiving cyclosporine
implies that other factors potentially contribute to this disorder (Ozdogan et al 1990).
These factors may include recipient characteristics such as a predisposition to
hypertension, age, family history of cardiovascular disease or recipient sex (Ozdogan et
al 1990). The effects of donor characteristics however, have not been widely reported.
Obesity may also influence hypertension development as it does in the general
population. Olivan et al (1989) observed that normotensive patients had less posttransplant weight gain than the transplant population as a whole. However, these
difference failed to reach statistical significance. In addition, there is some evidence to
suggest that corticosteroids play a role in the elevation of blood pressure through the
effects on arteriole sensitivity and sodium retention (Shapiro et al 1990). However, few
studies to date have investigated these effects.

It is therefore evident that hypertension is a complication of cardiac transplantation which
concerns a large proportion of this population. Although the effects of blood pressure
elevations on long-term outcomes of heart transplantation have not been defined it is
plausible that this disorder has adverse consequences for CAD development.
Pharmacological management and careful patient monitoring are likely to assist with
blood pressure control. Dietary and lifestyle factors such as weight reduction are

additional modes of therapy with few adverse side effects, thus their role in both the
treatment and prevention of this disorder is likely to be beneficial.

2.6. DIETARY INTAKE
2.6.1 Diet in Coronary Heart Disease
Diet has been identified as a corner stone in both the prevention and treatment of
cardiovascular diseases. Appropriate dietary modifications have been suggested to
reduce the risk of coronary heart disease by up to 20 per cent in the general population
(Gotto et al 1990). Decreased body weight, total cholesterol, LDL cholesterol, blood
pressure, blood triglycerides as well as increased HDL cholesterol have been shown to be
the result of dietary intervention (Schaefer et al 1981; Grundy and Denke 1990; Cheung
et al 1994). Although estimates vary as to the effect of diet on reducing cardiovascular
risk, it is generally agreed that it is a safe and effective means of heart disease prevention.

Predominant dietary factors in coronary heart disease include fat, cholesterol, sodium and
alcohol. Both total fat intake and fatty acid ratios are important in cardiovascular risk
reduction. The proportion of total fat in the diet with respect to energy intake is
associated with heart disease risk. This relationship, however, is not independent and is
thought to be mediated through the effects of fat intake on body weight, and the
association of a high fat intake with an increased intake of saturated fatty acids (Shrapnel
et al 1992).

The ratio of saturated, polyunsaturated and monounsaturated fatty acids is thought to be
more influential. Diets high in saturated fat, through their influence on LDL and total
cholesterol, have a significantly negative effect on heart disease risk (Keys et al 1986).
This relationship is strong and independent (Kromhout et al 1989). The role of
polyunsaturated fats is more controversial. The omega-3 polyunsamrated fatty acids have
been shown to reduce post-prandial lipemia, serum triglycerides and the tendency to
thrombosis (Mackness et al 1994; Zamperas et al 1994).

Whilst omega-6

polyunsaturated fats are thought to have an independent cholesterol lowering effect

(Shrapnel et al 1992). However, detrimental effects of polyunsaturated fat consumption
have also been suggested (Hodgson et al 1993). Monounsaturates, once thought to have
a neutral effect on serum cholesterol, have been shown to reduce LDL cholesterol when
substituted in the diet for saturated fats (National Health and Medical Research Council
1992). More recently, trans fats, resulting from the hydrogénation of vegetable oils,
have come into focus as an additional dietary consideration. Evidence however, suggests
that the effects of these fats on cholesterol levels are less than saturated fatty acids found
in animal products (Zock and Katan 1992). Consequently, dietary modifications of fatty
acids plays an important role in heart disease prevention.

The benefits of dietary cholesterol reduction have been met with much controversy. A
large number of studies investigating the relationship between cholesterol intake and heart
disease risk have produced inconsistent findings. However, it is thought that dietary
cholesterol may increase the risk of heart disease in sensitive individuals who cannot
down-regulate endogenous cholesterol synthesis in response to exogenous intake
(Shrapnel et al 1992). Hence modifying dietary cholesterol intake may be advantageous.

The intake of dietary sodium has also been related to the risk of cardiovascular diseases
(Elmer et al 1991). A high salt intake, in excess of physiological requirements, is
implicated in the development of hypertension. It is thought that this effect may be even
stronger in a subset of individuals who are sensitive to the effects of sodium (Shrapnel et
al 1992). As a total population approach to the prevention of cardiovascular diseases,
sodium restriction is controversial (Pecker and Laragh 1991). However, to date, there is
little evidence of adverse consequences of dietary sodium reduction (Elmer et al 1991).
Some researchers have even suggested that population based sodium restriction to 50 to
100 mmol daily may reduce the population mean blood pressure and reduce requirements
for anti-hypertensive pharmacological treatment (Beilin 1992). It is likely therefore, that
sodium restriction is a valid dietary action, particularly in high risk individuals.

Alcohol intake, depending on the level of consumption, can be detrimental or possibly
beneficial to heart disease risk. Excessive alcohol consumption has been observed to
increase serum triglycerides and blood pressure thus heart disease risk (Ahlawat and
Siwach 1994; Stamler et al 1991). In addition, heavy drinkers may be at increased risk
of other cardiovascular consequences including sudden cardiac death and cerebrovascular
accidents (Lester 1994). On the other hand, small quantities of alcohol, consumed on a
regular basis may offer a protective cardiovascular effect via its influence on HDL
cholesterol and platelet reactivity (Renaud and de Lorgeril 1992; Ganziano et al 1993).
Although it remains controversial as to whether the high density lipoprotein cholesterol
sub-class elevated by alcohol actually confers any cardiovascular benefits (Diehl et al
1988). As a result, reduced alcohol consumption is recommended.

An increased intake of carbohydrates and dietary fibre is recommended as an adjunct to
healthy heart diet therapy. The benefits of such a dietary pattern include reduction in fat
intake because of dietary substitution with these nutrients. Whilst fibre, particularly the
soluble variety has been shown to reduce total and LDL cholesterol through faecal bile
losses (Anderson et al 1991). Thus the benefits of increasing both fibre and carbohydrate
intake are evident in both heart disease prevention and treatment.

Diet clearly plays a role, both in the establishment and prevention of coronary heart
disease in the general population. Current dietary recommendations advocate a total fat
intake of less than 30 per cent of energy, with saturated fat accounting for less than 10
per cent of total energy intake. Sodium intake is recommended to be less than 100 mmol
per day and cholesterol below 300 milligrams per day, whilst alcohol intake should not
exceed 20 grams daily for women and 40 grams each day for men. In addition, fibre
intake is encouraged (Stewart 1990; Thomas 1994). Ideally, dietary intervention should
achieve a body weight appropriate to height (as indicated by BMI), blood cholesterol
levels below 5.5 mmol/L, triglycerides less than 1.8 mmol/L, and diastolic and systolic

blood pressure less than 90 and 150 mmHg respectively (Curtin University of
Technology 1992; Dwyer 1995).

2.6.2 Diet in Cardiac Transplantation

In heart transplant recipients, the role of diet in the aetiology of post-transplant CAD is
not as clear. The influence of pharmacological, immunological and infectious factors in
conjunction with a lack of available research, makes it difficult to ascertain the extent to
which diet can be implicated in the establishment of, or assist in the prevention of
cardiovascular complications.
Nutrition care of the heart transplant patient generally occurs as a three step process.
Prior to transplantation, patients often require intervention as a result of muscle wasting,
hypermetabolism and protein and fat malabsorption (Kumar and Coulston 1983).
Immediately post-transplant, patients may exhibit anorexia and post-operative catabolism
that warrants supplemental or enteral nutrition (Frazier et al 1985). However, more
frequently, appetite and nutritional status are significantly improved (C. Rawcliffe;
Personal Communications 1995). In the long term, the increased risk of developing
cardiovascular complications is an indication for nutrition intervention (Poindexter 1992).
Pre and immediate post-operative dietary requirements, considerations and interventions
are beyond the scope of this study. This review is concerned specifically with the long
term dietary management of heart transplant recipients.
At St. Vincent's Hospital, long term nutritional management involves assessment and
education by a Clinical Nutritionist. Dietary recommendations are based on a healthy
heart diet. This includes, less than 30 per cent of energy from fat, less than 10 per cent
of energy from saUirated fat, less than 300 milligrams of cholesterol per day, an increased
dietary fibre intake and no added salt. These dietary guidelines are compatible with those
recommended by the National Heart Foundation for the prevention of cardiovascular
disease in the general population (Shrapnel et al 1992).

Similar guidelines exist in other heart transplant centres. Approximately 80 per cent of
transplant centres in the United States include a dietitian as a member of the cardiac
support team. The most common long term post-transplant dietary recommendation is a
2-4 gram sodium restriction, low fat, low cholesterol diet. This is advocated in 30 per
cent of transplant centres.

However, often, a more stringent diet which includes

restricted dietary fat to less than 30 per cent of energy, restriction of saturated fat to less
than 7 per cent of energy and dietary cholesterol intake of less than 200 milligrams per
day is recommended (Moore et al 1991).

The few studies reporting on the diet of post-transplant patients suggest that the dietary
intake of this population generally complies with recommendations. Total fat intake has
been reported to be approximately 33 per cent of energy in one French study (Salen et al
1994). This is similar to the reported intakes of the Australian population (Baghurst et al
1994). In the same study, saturated, polyunsaturated and monounsaturated fat accounted
for 12, 7 and 11 per cent of energy respectively. Alcohol and fibre intakes in this
population were reported to be low. The researchers concluded that compliance with the
dietary advice provided by doctors or dietitians was high in the post-transplant population
(Salen et al 1994). The results of this study, however must be interpreted with care as
the twenty-four hour recall as used to assess dietary intake does not account for intraindividual variation in dietary intake (Cameron and van Staveren 1988). Whilst cultural
factors reduce the comparability of these findings with the Australian population.

In comparison, subjective assessments of dietary intake as undertaken in some studies
indicate that compliance with dietary recommendations is generally sub-optimal. Keogh
(1987), in studies on hyperlipidaemia, suggested that compliance with low fat, low
cholesterol dietary advice was often poor. This claim was based upon the high incidence
of obesity and hyperlipidaemia in this population and was not substantiated with evidence
regarding actual dietary intakes.

Keogh also noted in her study, the possible role of

lifestyle factors in reducing cardiovascular risk and the need for more stringent efforts for
weight control, hence dietary intervention, in the transplant population.

The degree to which current recommendations for the long term management of heart
transplant recipients reduce cardiovascular risk, is not known. In renal transplant
patients, who tend to have similar clinical profiles, evidence suggests that diet therapy is a
safe and effective means of treatment. Dietary modifications including a reduction in
saturated fat, cholesterol, simple sugars and alcohol intake have been associated with
significant reductions in plasma cholesterol and body weight in this population (Disler et
al 1981). Little has been reported on the relationship between these known risk factors
and dietary intakes in the heart transplant population.

Ragsdale (1987) has attempted to show improved nutritional status as a result of dietary
intervention by comparing nutrition intervention in the initial stages of a post-transplant
nutrition program, with later more stringent interventions. The first 10 heart transplant
recipients at the Indiana Methodist Hospital were placed on a type IIA
hyperlipoproteinemia (less than 300 milligrams of cholesterol), restricted simple sugar,
and 2 - 4 gram sodium-restricted diet. Dietary follow up in these patients was limited.
Of these patients, five gained 20 kilograms or more above their pre-transplant weight and
four died as a result of accelerated CAD within eighteen months. Since the initiation of a
nutrition education program which emphasised less than 25 per cent of energy from fat,
10 per cent monounsaturated fat and 10 per cent saturated fats, as well as regular dietetic
intervention, a larger proportion of patients were living beyond one year. At the same
time,

the incidence of obesity and mortality from CAD was reduced. These

improvements were attributed to changes in medications, improved dietary monitoring
and increased patient and family involvement with dietary modifications. Although this
study suggests that dietary intervention may play a role in improving the long term
cardiovascular health of transplant recipients, the statistical significance of any changes

and the extent to which improved health outcomes were related to dietary intervention
were not reported.

There is some evidence that a Mediterranean style of eating may be effective in the long
term management of heart transplant patients. The Mediterranean diet, as popularised by
The Seven Countries Study is low in total fat, and saturated fat and high in monounsaturates, and is associated with a low cardiac mortality rate in the general population
(Kromhout et al 1989). In heart transplant recipients, the possible benefits of consuming
such a diet include a reduction in LDL cholesterol as a result of a low saturated fat intake,
reduced body weight occurring in conjunction with less calories from fat, and a reduced
oxidation of lipoproteins to foam cells as a result of the effects of oleic acid, a monounsaturate (National Health and Medical Research Council 1992; Kromhout et al 1989).
Salen et al (1994) in a dietary intervention study evaluated the effects of the
Mediterranean diet on cholesterol levels in post-transplant recipients.

Forty one

transplant recipients with hypercholesterolaemia were studied for an eighteen month
period. They were provided with diet counselling to reduce total fat, saturated fat and
polyunsaturated fat to less than 30, 10 and 6 per cent of total energy respectively.
Saturated and polyunsaturated fats in the diet were replaced with monounsaturates
including olive and rapeseed oils. Participants were advised to avoid rich sources of
polyunsaturates, to select low fat dairy products, lean meats and increase fruit, vegetable
and cereal consumption, as well as drink moderate amounts of wine during meals.

The mean dietary intake one year after initial counselling was significantly lower in total
calories and saturated fat. Intakes of polyunsaturates, cholesterol and total fat were
lower, whilst monounsaturated fat intake was higher, these differences however, were
not statistically significant. The biochemical profile of participants showed significantly
reduced total and low-density lipoprotein cholesterol after diet modification. Body
weight did not significantly differ, nor did high density lipoprotein cholesterol levels or
arterial blood pressure.

Although immunosuppressive therapy was progressively

reduced during the period of the study, there were no significant changes in blood
pressure or blood triglycerides. Hence, it was concluded that changes in the biochemical
profile of participants was the result of dietary intervention. The potential role of diet as
an alternative to pharmacological treatment in these patients is therefore promising.
However, the impact of dietary intervention on long term survival could not be
determined due to the short time period of the study and absence of a control group.
The need for a large controlled study to confirm these findmgs is warranted.

The benefits of dietary sodium restriction in the post-transplant period have also been
implied. Sodium intake has been linked with hypertension in epidemiological studies,
clinical trials and animal studies (Shrapnel et al 1992). Singer et al (1994) found similar
results in the heart transplant population. In a study on twelve transplant recipients, it
was reported that a sodium intake of ten mmol per day substantially reduced systolic
blood pressure, whilst a 350 mmol per day intake was associated with increased blood
pressure (Singer et al 1994). The effect was similar to that found in non-transplant
recipients with essential hypertension. The potential for sodium restriction as a nonpharmacological alternative to the treatment of post-transplant hypertension is therefore
evident. However, it must be noted that, in real life, the 10 mmol daily intake of sodium
on the low salt diet as implemented in the above mentioned study is largely unachievable
and less than recognised human physiological requirements (National Health and Medical
Research Council 1991). Further studies are required determine the role of currently
recommended level of sodium intake in blood pressure control in this population.

The possible role of a multitude of factors in post-transplant CAD, makes the contribution
of diet in both its development and treatment largely controversial. Other studies
supporting those of Salen et al (1994) and Singer et al (1994) are limited. There is
however, some contradictory evidence which suggests that dietary intervention has little
effect on reducing body weight, serum lipids or blood pressure in the post-transplant
recipient (Eich et al 1990). Ballantyne et al (1992) in a six year follow up of transplant

patients, reported that the American Heart Foundation Step One Diet had little effect on
reducing serum cholesterol, triglycerides or LDL cholesterol levels. However, it should
be noted that compliance with the dietary recommendations was not measured in this
study. Hence, these results may not reflect the true advantages of dietary intervention.

The role of dietary intervention has also been questioned by Becker et al (1988). They
found no correlation between LDL cholesterol, total cholesterol or triglyceride levels and
dietary fat intake. As a result it was concluded that low levels of dietary fat and
cholesterol demonstrate little effect on serum lipids. Again caution must be taken in the
interpretation of these results. Firstly, the actual dietary fat intake of the sample was not
reported in the study. The results therefore rely on the researchers assessment of what
constitutes a low fat diet. In addition, a similar dietary fat questionnaire as that used to
measure intake has recently been reported to lack the sensitivity and specificity to be used
as a single assessment method (Caan et al 1995). Conclusions regarding dietary intake
and contribution to CAD, therefore remain controversial.

Cardiac transplant patients are clearly at high risk of developing long term cardiovascular
complications. Although diet has been established as a key factor in the coronary heart
disease seen in the general population, risk factors in heart transplant recipients are not as
clearly defined. Further investigation into the effectiveness of diet therapy, the dietary
intake of this population and the optimum dietary recommendations is needed to assist in
the prevention and non-pharmacological management of post transplant CAD.

2.7 MULTIPLE CARDIOVASCULAR RISK FACTORS
AND CAD DEVELOPMENT
The evidence from the literature to date clearly suggests that the role of conventional
cardiovascular risk factors in the development of CAD following heart transplantation
remains highly controversial. Although the underlying cause of CAD in the cardiac
transplant recipient has yet to be determined, evidence suggests that a combination of
immunological and non-immunological factors influence CAD development. In support
of this hypothesis, there is considerable evidence that risk factors including
hyperlipidaemia, obesity, hypertension and diabetes mellitus, in conjunction with dietary
and lifestyle factors contribute to this anomaly.
Although each of the risk factors have been discussed separately in this report, the
multifactorial nature of this disorder is noteworthy. Obesity for example is likely to affect
other risk factors such as diabetes and hypertension. Whilst dietary intake has multiple
consequences for cardiovascular profile. It has been suggested in some studies that the
affect of these risk factors is additive on CAD development. Winters et al (1990)
demonstrated that percentage luminal narrowing was increased with the successive
addition of each conventional cardiovascular risk factor in cardiac transplant recipients.
In patients with a BMI >27, they reported a rise in luminal narrowing from 66 to 80 per
cent. This is similar to findings in the general population which have suggested that the
existence of multiple risk factors has adverse consequences for cardiovascular profile.
Clearly, an effective means of prevention would be beneficial to both quality of life and
survival in this population. However, inconsistencies in the literature to date, warrants
further research to investigate the underiying aetiology, prevalence and preventative
options for this major limiting factor in the long term survival of cardiac transplant
recipients.

2.8. METHODOLOGY
2.8.1 Body Weight Assessment
Body weight can be measured using a number of different anthropometric assessment
methods. In the present study, body mass index, waist-to-hip ratio and waist
circumference have been selected as determinants of cardiovascular risk.
In clinical practice, the body mass index (BMI) is the most frequently defined measure of
overweight and obesity. BMI is a measure of the ratio of weight (kg) to height (m)2 and
is useful for comparing body weights between persons of differing height. A BMI in
excess of 25 is constitutes overweight, whilst that greater than 30 is characteristic of
obesity (Bray 1985). These classifications are shown in table (1) below.
BMI
<19
20-25
26-30
31-40
>40

CLASSIFICATION
Underweight
Healthy Weight
Overweight
Obese
Morbidly Obese

Table 2.7.1 Classifications of Body Weight based on BMI
(Adapted from Bray 1985)
The BMI is advantageous as a measure of body weight in that it is easy to calculate and
provides a simple total body weight classification criteria which can be used to assess
potential health risks (Bray 1985). However, this technique of anthropometric
assessment provides little information on the distribution of body fat and there is some
evidence that BMI is not predictive of cardiovascular risk (Loos and Halais 1991;
Hodgson et al 1994). Some researchers have also suggested that the BMI misclassifies

obese patients when compared with measures of body fat (Hortobagyi et al 1994). Thus
methods to assess body composition may provide a more useful indication of
cardiovascular risk than total body weight.

One of the most commonly employed methods to determine the site of fat deposits is the
waist-to-hip ratio (WHR). The WHR assessment technique involves measuring both the
waist and hips with a non-stretchable tape measure and calculating the resultant ratio.
The validity of this method for determining body fat distribution has been reported by
Loos and Halais (1991) who established that this measure was a valid means of
identifying increased cardiovascular risk and increasing abdominal fat deposition. Ross
et al (1992) on the other hand, compared similar anthropometric variables with magnetic
resonance imaging and concluded that WHR was not a good indicator of visceral
adiposity.

The inconsistencies in the literature on WHR clearly make it difficult to assess the validity
of this method for body fat assessment. It is likely that the wide variation in WHR
methodologies contributes to methodological problems. To date, over 18 different sites
for measuring the waist and hips have been identified (Loos and Halais 1991) each which
been reported to significantly alter the WHR (Alexander and Dugdale 1992). Houmard et
al (1991) have attempted to clarify this issue by comparing five different sites for WHR
assessment with metabolic variables. The results of which suggest that measures at
minimal waist / maximal hips, umbilicus / maximal hips, umbilicus / greater trochanters
and umbilicus / iliac spine are most strongly associated with indices of lipid and
carbohydrate metabolism. Thus it is possible that a number of sites may be utilised to
determine the degree of cardiovascular risk.

A potential problem in WHR assessment is the use of different cut-off points to indicate
cardiovascular risk. Some researchers suggest that a WHR of <0.9 for males and <0.8
for females are the most desirable for cardiovascular health (Egger 1992). Elsewhere

however, levels of 0.95 and up to 1.0 have been suggested for males and 0.85 and 0.75
for females (Loos and Halais 1991; Despres et al 1992). Clearly, the use of these cut off
points is likely to be dependant on the chosen site and will ultimately affect the degree of
cardiovascular risk. The cut-off points of 0.9 for males and 0.8 for females have been
shown by several researchers to correspond with cardiovascular risk at the site of the
umbilicus / iliac spine (Alexander and Dugdale 1992; Egger 1992).

The reliability of WHR assessment technique appears to be satisfactory. Several recent
studies have shown that repeated measures produce similar results. Rasmussen et al
(1993), demonstrated that intra-observer variation was low in the measurement of WHR
and concluded that repeated measurements were not necessary in clinical trials. Other
researchers have demonstrated that multiple measures differ by up to 0.62 cm for the
waist and 1.24 cm for the hips. As a result, WHR variation is 0.02 (Alexander and
Dugdale 1992). Similarly, Loos and Halais (1991) reported the mean difference between
two measures of WHR to be less than 1 per cent.

More recently, waist circumference has been identified as a better indicator of abdominal
fat distribution and consequent cardiovascular risk. Pouliot et al (1994) compared
visceral adipose tissue using computer tomography with measures of waist
circumference, abdominal sagittal diameter and WHR.

They found that waist

circumference measures >100 cm and sagittal diameter >25 cm were the most likely to be
associated with the metabolic disturbances which affect cardiovascular risk. This is
supported by more recent studies from Lean et al (1995) who demonstrated that waist
circumference was useful in identifying increased cardiovascular risk, independent of
WHR. Waist circumference could therefore be utilised as either an indépendant or
additional measure of body fat distribution.

2.8.2 Dietary Intake Methodology

The diet history, as described by Burke (1947) is a method of measuring the usual dietary
intake of individuals. This process involves an extensive interview to obtain information
regarding foods consumed and frequency of consumption and methods of preparation.
As with other means of dietary assessment, there are both advantages and limitations to
using this method as a tool in research.
The diet history is advantageous in that it requires little time commitment from
respondents, as a result, participation rates may be increased (Cameron and van Staveren
1988). As the focus of this method is on usual it also allows for the assessment of
intake over a longer period than other methods (eg. 24 hour recall, 3 day food records).
In addition, it allows for exploration of food preparation techniques and probing for
further details regarding intake (Thompson and Byers 1994).
Major limitations of the diet history include the large subjective component required in
estimating intake, as participants are required to make judgements regarding usual foods
and serve sizes. Thus actual intake is subject to possible misinterpretation. The diet
history is also problematic in the fact that data collection requires participants to have a
usual dietary pattern. As a result, individuals with inconsistent intakes cannot be
included in analysis. In addition, the usual aspect of this method, frequently results in
omission of less frequent, but possibly important dietary contributions (Freudanheim
1993).
The validity of the diet history method is subject to some controversy. A number of
researchers have found that nutrient intakes tend to be over estimated when compared
with other methods (Nes et al 1991). Whilst Black et al (1993), have reported that
weight-conscious individuals may actually underestimate usual intake with this method.
On the other hand, some have suggested that an in depth history is a relatively valid
means of dietary assessment (Freudanheim 1993). Whilst, other researchers have

reported a correlation between this method and biochemical indicators (van Staveren et al
1985). However, this has not been consistently demonstrated.

Overall, the diet history method, as with other means of dietary intake assessment is
subject to inaccuracies. As a result, it is recommended that nutrient intakes be interpreted
as relative rather than absolute. To accommodate this in research, Bourke (1947) has
recommendaed that individuals be ranked into high, moderate and low classifications for
the range of nutrients examined. As a result, using a range of intakes should reduce
inaccuracies evident with this measurement technique.

3. METHODS
3.1 Setting
This project was undertaken at St. Vincent's Hospital (SVH), Sydney from August to
November 1995. At the time of writing, SVH was a 400 bed teaching hospital and the
only institution performing cardiac transplantation within New South Wales.

3.2 Sample
The sample was selected from the St. Vincent's Hospital heart transplant population who
had received a successful orthotopic transplant within the past 12 to 24 months. This
time frame was selected because there is evidence to suggest that risk factors for heart
disease occur within the first year post-transplant.

In addition, biochemical and

anthropometric indicators are regularly monitored during this period and are therefore
available for analysis.

Fifty four orthotopic heart transplants were performed at SVH from July 1993 to
November 1994. Of these, eight patients had died, leaving of 46 transplant recipients.
The small size of the transplant population required all patients who met the inclusion
criteria to be contacted for participation.

3.3 Inclusion Criteria
For inclusion in the study, the patients had to meet the following criteria:
i) Successful orthotopic heart transplant within past 12 to 24 months
ii) Over 18 years of age
iii) No other medical condition that may affect nutritional stams (eg. liver or renal disease,
cancer)
iv) No special physiological requirements (eg. pregnancy)

3.4 Participant Contact
Patients who met the above criteria were selected from SVH records. Each person was
sent a letter explaining the aims and objectives of the project and the nature and extent of
participant involvement (refer to appendix 11.2). This was followed up with a telephone
call to each patient. A convenient date (between August and October 1995) and venue
was arranged with those who agreed to participate.

3.5 Ethical Issues
Approval was obtained from the SVH and University of Wollongong Ethics Committee's
(refer to appendix 11.1). Informed consent was obtained by a written consent form, a
copy of which was retained by both the researcher and participant (Refer to appendix
11.3). Each participant was identified by their hospital transplant number to ensuring
confidentiality. Information which identified participants was not removed from SVH.

3.6 Data Collection
The study involved two type of data collection - retrospective information from SVH
medical records and information provided by the participant. These are described below.

Demographic Data
Da^ta describing the characteristics of each participant, including age, sex, initial
diagnosis, medication protocols and waiting period for transplantation was obtained from
SVH medical records.

Anthropometric Data
Recent / current body weight was obtained from SVH outpatient medical notes and
transplant records. If weight was not recently recorded this was obtained by weighing
participants. Pre-transplant body weight, weight at 1, 3, 6, 12, 18 and 24 months posttransplant (as appropriate) was obtained from SVH pre-transplant assessment clinic and

outpatient medical notes. Participants were weighed on the same set of scales at each
time interval. However, a number of participants were weighed on a smaller set of scales
if their recent weight had not been recorded. The same set of scales was used for each of
these participants. Weight was recorded to the nearest 0.5 kg. Height was obtained
from SVH pre-transplant assessment clinic records. The accuracy of this information
was verbally confirmed with participants. Height was recorded to the nearest 1.0 cm.
Waist to hip ratios were determined by measuring participants waist and hips with a
plastic tape measure. Waist measurement was determined at the level of the umbilicus,
whilst hips were measured at the superior iliac crest. All measurements were taken while
participants were lightly clothed and upright with arms at their sides. Each site was
measured twice and the average of the two readings was recorded.

Dietary Intake

To obtain information regarding usual dietary intake, participants were each interviewed
for approximately one hour. A modified version of Burkes original diet history was the
selected method (Burke 1947). The aim of the diet history was to quantify usual dietary
intake and derive qualitative information about eating behaviours. Participants were
asked to describe their usual dietary intake in as much detail as possible. A food
frequency questionnaire was used as a crosscheck and to further quantify diet history
data. The three day food record as used by Burke was not included due to time
constraints. Food models, standard measures and participant drawings were used to
quantify serve sizes.

Participants were also asked a series of additional questions. This included describing
methods of food preparation, use of convenience and takeaway foods, and brands and
varieties of food products consumed. Each participant was also asked to rate present
appetite (poor, good, excellent), changes in appetite since transplantation (increased,
decreased, no change) and noticeable changes in weight since transplantation (increased,
decreased, no change).

Finally, to determine current level of physical activity.

participants were asked if they engaged in any regular exercise and if yes, the duration
and frequency of activity.

Biochemical Indicators
Total cholesterol and blood triglyceride levels were obtained from SVH outpatient
medical notes and transplant records. These measurements were obtained using standard
hospital collection and analysis procedures. This data was recorded at pre-transplant, and
1, 3, 6, and 12 as well as 18 and 24 months post-transplant (where applicable).

Blood Pressure
Blood pressure measurements were obtained from SVH outpatient medical notes and
transplant records. This data was recorded at pre-transplant, and 1, 3, 6, and 12 as well
as 18 and 24 months post-transplant (where applicable). The administration of antihypertensive medications or a diastolic blood pressure exceeding 95 mmHg were
considered to constitute hypertension. The degree of blood pressure control over time
was noted for this population.

Diabetes Mellitus
The presence or absence of diabetes mellitus was also noted, as was mode of control (eg.
diet, oral hypoglycaemic agents, insulin)

3.7 Data Analysis

The collected data was analysed as follows:

Demographic Data
The participants age, sex, medications and initial diagnosis were used to describe the
characteristics of the sample. Descriptive statistics were used to provide this information.
Cholesterol Levels

Cholesterol levels were analysed at pre-transplant and 1,3,6,12,18 and 24 months posttransplant using an analysis of variance (ANOVA). A t-test was used to determine any
significant changes between each increment. The proportion of patients with
hypercholesterolaemia at each point in time was also noted.
Triglyceride Levels

Changes in triglyceride levels were described where available. Due to missing data, these
were not statistically analysed.
Body Weight

Weights and heights were converted into the Body Mass Index (BMI). The BMI of
participants was analysed at pre-transplant and 1,3,6,12,18 and 24 months posttransplant using an analysis of variance (ANOVA). A t-test was used to determine any
statistically significant changes at each increment. Average weight gain at each period
and the proportion of patients in the underweight, healthy weight, overweight and obese
categories of the healthy weight range were described for the group.
Waist-to-Hip Ratio

The Waist-to-Hip ratio was used to identify the occurrence of abdominal obesity in the
post-transplant population. The mean ratios were compared to the recommended values
of 0.80 for females and 0.90 for males. A t-test was used to determine any statistically
significant differences.
Blood Pressure

Diastolic and systolic blood pressures were recorded at 1,3,6,12,18 and 24 (where
applicable) months post-transplant and analysed using an analysis of variance (ANOVA).
The proportion of patients with hypertension and degree of blood pressure control was
noted over time.

Diabetes Mellitus
The occurrence of diabetes and mode of control were described for this population.

Dietary Intake
Dietary intake data was analysed quantitatively for total fat, saturated, monounsaturated
and polyunsaturated fat, carbohydrate, protein, fibre, alcohol, cholesterol and sodium
using the Diet Version 2.05 ( Xyris Software, Aust. Pty. Ltd. 1989) nutrient analysis
program. Dietary intake data was compared to the current nutritional recommendations
for heart transplant recipients. A t-test was used to determine the extent to which the
mean intake for this population differs from these recommendations.

Transplant

recipients were ranked into categories according to low, medium or high levels of dietary
intake for the analysed nutrients.

4. RESULTS
4.1 Patient Characteristics
Of the 46 patients contacted, 17 were excluded from the study. Two of the patients had
developed chronic renal failure, one had liver disease, one was less than 18 years of age,
five lived interstate and were not attending SVH during the period of the study and eight
were not able to be contacted. Of the remaining 29 patients, two declined to participate.
The remaining 27 patients made up the study population.
Table (1) lists the demographic characteristics of the patient population including age,
sex, time since transplantation and pre-transplant waiting period.

Variable

Mean ±SD

Range

Age (years)
Sex

48.7 ± 7.9
Male: 23
Female: 4
17.7 ± 4.67

(36 - 66)

137 ± 162.8

(1 - 546)

Post-transplant Period
(months)
Waiting Period
(days)

(11-25)

Table 4.1: Characteristics of the patient population (N= 27)
Age was recorded as that at time of participation in the study. The age range of
participants was from 36 to 66 years, with mean of 48.7 years. Time since
transplantation was also recorded at time of participation. The post-transplant period
ranged from 11 to 25 months with a mean of 17.7 months. This deviation from selection
criteria is the result of participant availability. There were more males than females

participating in the study, with a male to female ratio of approximately 6:1. This is
similar to the pattern seen in the total transplant population. Mean waiting period for
transplantation was 137 days. Waiting time ranged from one to 546 days, depending on
the availability of a of suitable donor.
The pre-operative diagnoses for the study population are shown in Table 4.2. The most
frequent diagnosis requiring transplantation was idiopathic cardiomyopathy or disease of
the myocardium of unknown cause. Second to that was ischaemic heart disease,
followed by valvular myopathy. Less frequent diagnoses included myocarditis,
congenital heart disease and periparmm myopathy.

Diagnosis
Idiopathic Cardiomyopathy
Ischaemic Heart Disease
Valvular Myopathy
Myocarditis
Peripartum Myopathy
Congenital Heart Disease

Number
13
9
2
1
1
1

Table 4.2: Pre-operative diagnosis of heart transplant recipients (N=27)
All participants in this study were receiving triple-drug immunosuppression with
prednisone, azathioprine and cyclosporine. Two participants were also receiving Adifax,
an appetite suppressant, at the time of the study.

4.2 Lipid Levels
Hyperlipidaemia was defined as a serum cholesterol exceeding 5.5 mmol/litre,
triglyceride levels greater than 1.8 mmol/litre or by the administration of lipid lowering
agents. Prior to transplantation, 30 per cent of patients displayed hyperlipidaemia. At
three months this increased to 44 per cent and at twelve months 41 per cent of transplant
recipients were hyperlipidaemic. Figure 4.1 shows these results.
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Mean total cholesterol levels were found to differ over time with an analysis of variance
(ANOVA). A t-test was performed to test the significance of any differences at each
interval in time. Prior to transplantation the mean cholesterol level was 4.4 i 1.3
mmol/litre. At three months post-transplant, this increased significantly (t=-2.86 p<0.01)
to 6.1 ± 1.6 mmol/litre. Over time, cholesterol remained elevated at a mean of 5.8 ± 1.1
mmol/litre, 5.5 ± 0.8 mmol/litre and 5.5 ± 0.95 mmol/litre at six, twelve and eighteen
months respectively. However, no further significant increases in cholesterol occurred
after this time. In addition, the mean cholesterol for the four patients at 24 months posttransplant was 5.3 mmol/litre. Figure 4.2 represents these results.
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Figure 4.2 : Changes in total cholesterol over time in cardiac transplant
recipients

Triglyceride levels over time, were not readily available for all patients. Statistical
analysis of these results was therefore not performed. Figure 4.3 below shows a trend to
increasing triglycerides at 3 months post-transplant, with a progressive decline over the
following months.

5

T

J
'o
B
00

(D 3 -'C
CJ
'C
H

s

Ui
(L> 1 -C/D

0 -L
Pre

6 Months

12 Months

18 Months

Months Post-Transplant

Figure 4.3: Changes in triglyceride levels over time in cardiac transplant
recipients

4.3 Body Weight
Participants were classified as being underweight, healthy weight, overweight or obese
as calculated by BMI. The proportion of heart transplant patients in the overweight and
obese categories of the healthy weight range increased with time from one month posttransplant. Prior to transplant, 44 per cent of patients were above the desirable weight for
height, at one month post-operative, this decreased to 22 per cent of patients. After this
time the number of overweight and obese patients increased to 52 per cent at three
months, 56 per cent at six months and by twelve months post-transplant, 56 per cent of
recipients were overweight, with one third of these being classified as obese. The
number of patients in the underweight and healthy weight ranges showed a
corresponding decrease with time. Refer to Figure 4.4.
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Figure 4.4: Weight status of the post-cardiac transplant population over
time

Changes in body weight were evident over time with an analysis of variance (ANOVA).
A t-test was performed to determine the significance of these changes. The mean body
mass index for participants prior to transplantation was 24.7 ± 3.3. At one month postoperative this decreased significantly to 23.9 ± 3.5 (t=3.18 p<0.01). A steady increase
in body weight that was significant at each increment was evident from three months
post-transplant, up to twelve months. At three months mean weight increased to 25.1 ±
3.69 (t=-4.22 p<0.01), at six months weight increased again to 26.3 ± 3.49 (t=-5.08
p<0.01) and at twelve months post-transplant, the mean BMI was significantly higher at
27.1 ± 4.6 (t=-3.02 p <0.01). This is equivalent to a mean weight gain of 7.8 ± 7.42
kilograms from pre-transplant to twelve months post-transplantation. Significant changes
in weight were not evident again after this time. Figure 4.5 represents this data.
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Figure 4.5: Changes in body mass index (BMI) over time in cardiac
transplant recipients

To determine any differences between post-transplant body weight and weight prior to
the onset of cardiac failure, participants ranked their present weight as increased,
decreased or no change when compared to pre-transplant usual weight. Seventy per cent
of patients indicated that their weight had increased, 11 per cent said it had decreased and
19 per cent reported that their current weight was comparable to healthy pre-transplant
weight Refer to Table 4.3 below.

Weight

change

Percentage

No Change

19%

Increased

10%

Decreased

11%

Table 4.3: Self-reported changes in usual weight
following cardiac transplantation

4.4 Body Fat Distribution
Indicators of body fat distribution were measured at the time of participation in the study.
These included waist-to-hip ratio (WHR) and waist circumference. A WHR exceeding
0.90 for males, 0.80 for females and a waist circumference greater than 100 cm were
considered to pose cardiovascular risk. The mean WHR for males was 1.01 ± 0.06. A
t-test revealed that this was significantly higher than recommended (t=8.713 p<0.01).
The mean WHR of 0.80 ± 0.06 for females did not indicate cardiovascular risk. Overall,
88 per cent of the total transplant population displayed a WHR larger than desirable. The
mean waist circumference was 100.7 ± 15.7 cm and 33 per cent of participants had a
circumference measure greater than 100 cm. Table 4.4 below shows the mean, range and
t-test values for these variables.
Variable

Meant SD

Range

Recom,

Waist Circumference

100.7 ± 15.7

85.0 - 132.5

< 100 cm

NS

Males (N= 23)

1.01 ±0.06

0.94- 1.10

<0.90

p<0.01

Females (N=4)

0.80 ±0.06

0.75 -0.89

<0.80

NS

Waist-to-Hip Ratio

P Value

Table 4.4: Indicators of body fat distribution in male and female cardiac
transplant recipients
4.5 Diabetes Mellitus

Post-transplant diabetes mellitus occurred in five (19%) of the twenty seven participants.
Two participants (7%) also exhibited non-insulin dependant diabetes mellitus prior to
transplantation which was evident in the post-operative period. Two of the patients were
maintained on insulin, whilst the remaining five were controlled with sulphonylurea oral
hypoglycaemia agents.

4.6 Blood Pressure
Hypertension was determined as a blood pressure exceeding 95 mmHg diastole or the
administration of anti-hypertensive medications. At one month post-operative, 52 per
cent of participants displayed hypertension. This increased to 60, 67 and 73 per cent at
three, six and twelve months respectively. This is shown in figure 4.7 below.
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4.6 Hypertension over time following cardiac transplantation

Mean diastolic and systolic blood pressures for the post-transplant population are shown
in figure 4.7. Blood pressure over time did not change significantly with an analysis of
variance (ANOVA). At one month post-operative mean blood pressure for the group was

79 / 127 mmHg. At three, six and 12 months these values were 85 / 132, 86 / 137 and
83/ 134 mmHg respectively. Over time following transplantation, none of the transplant
recipients displayed persistent uncontrolled hypertension.
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4.7 Changes in mean blood pressure over time following cardiac
transplantation

4.7 Dietary Intake
All heart transplant recipients had been seen by a dietitian in the post-operative period.
Table 4.5 below shows the mean dietary intakes of total fat, saturated fat, protein,
carbohydrate, fibre, cholesterol and sodium. A t-test was performed to compare nutrient
intakes with current recommendations.

Nutrient

Mean + SD

Recom.

PValue

Fat
(% energy)
Saturated Fat
(% energy)
Carbohydrate
(% energy)
Protein
(% energy)
Cholesterol
(milligrams)
Fibre
(grams)
Sodium
(mmol)

31.7 ±4.73

<30%

<0.05

11.1 ±3.01

< 10%

<0.05

41.5 ±7.31

55 - 60%

<0.01

21.8 ±3.78

15 - 20%

<0.01

317 ± 157.0

< 300 mg

NS

31.1 ± 10.1

25-30g

121.9 ± 36.5

40 - 100 mmol

-

<0.01

Table 4.5: Dietary intake of cardiac transplant recipients compared to
recommendations

Fat

The mean intake of total fat was significantly higher than the current dietary
recommendations (t=1.84 p<0.05). There was considerable variability in regards to fat
intake. A low fat diet was considered to be <30 per cent contribution to energy, a
moderate fat diet was between 30 to 35 per cent of energy and a high fat diet was at
intakes above this level. The percentage of patients with low, moderate and high fat
intakes was 37, 37 and 26 per cent respectively. The range of fat intakes is shown in
figure 4.8 below.

Saturated Fat
The mean intake of saturated fat was 11.1 ± 3.01 grams per day. This was significantly
higher than the currently recommended < 10% of energy (p< 0.05). Figure 4.8 shows
the range of saturated fat intakes in transplant recipients. A low intake was regarded to be
<10 per cent of energy as recommended, a moderate was from 10 to 15 per cent of
energy and a high at intakes above this level. Thirty seven, 56 and 7 per cent of
recipients respectively displayed intakes at these levels.

Carbohydrate
The mean carbohydrate intake of the transplant population was significantly lower than
the currently recommended 55 to 60 per cent of energy (t=-9.78 p<0.01). The range of
carbohydrate intakes is shown in figure 4.8 below. A low carbohydrate intake of <40
per cent of energy was demonstrated in 44 per cent of transplant recipients. A moderate
intake of 40 to 55 per cent of energy was found in 56 per cent of participants whilst no
participants had a high carbohydrate intake (>55 per cent of energy) as recommended.

Protein
Protein intake of the transplant population contributed to a mean 21.8 per cent of total
energy.

This was significantly higher than the recommended 15 to 20 per cent

contribution of protein to energy intake (t=2.50 p<0.01). The range of protein intakes is

shown in figure 4.8 below. A low protein was regarded as <20 per cent of energy. This
was demonstrated in 26 per cent of participants. Moderate intakes of 20 to 25 per cent of
energy were found in 52 per cent, whilst 22 per cent displayed high intakes of >25 per
cent of energy.

Cholesterol

The mean cholesterol intake for the heart transplant population was 317 mg per day. This
was higher than the currently recommended 300 mg daily. However, the difference was
not statistically significant. Cholesterol intake was rated as low, <300 milligrams (as
recommended), moderate, 300 to 400 milligrams and high >400 milligrams daily. Low,
moderate and high cholesterol intakes were found in 55, 30 and 15 per cent of
participants respectively.

Refer to figure 4.8.

Fibre

The mean fibre intake for the heart transplant population was 31.1 gram per day. This
level meets the current recommendations for fibre. The range of fibre intakes, low (<20
grams), moderate (20 - 30 grams) and high (>30 grams) were found in eight, 44 and 48
per cent of participants respectively. This is shown in figure 4.8.

Sodium

The mean sodium intake for this population was 121.9 mmol daily.

This was

significantly higher than the currently recommended 40 to 100 mmol per day (t=2.82
p<0.01). The range of intakes is shown in figure 4.8. A low intake was considered to
be <100 mmol as recommended, this was evident in 29 per cent of transplant recipients.
A moderate intake of 100 to 150 mmol was reported by 52 per cent, whilst intakes above
this level were evident in 19 per cent of participants. Figure 4.8 shows these results.
The salt (sodium chloride) avoidance practices of transplant recipients were also noted in
the study. Table salt use was reported by 15 per cent of participants, the use of salt in
cooking by 11 per cent and both practices by 7 per cent of transplant recipients.

Alcohol
Alcohol intake was classified as low, moderate or high risk based on National Heart
Foundation guidelines (refer to appendix 11.5). Thirty seven per cent of transplant
recipients reported that they were non-drinkers, the remaining 63 per cent were classified
as low risk for alcohol intake. Refer to figure 4.8.
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Figure 4.8: Classifications of dietary intake for selected nutrients in the
post-cardiac transplant population

Current Eating Pattern
Seventy one per cent of heart transplant recipients said that they were currently following
some kind of special diet. A low fat diet was the most frequent, followed by a reduced
fat and salt diet. These results are presented in table 4.6 below.

Diet

Percent

No special diet

29%

Reduced fat

29%

Reduced fat / salt

22%

Diabetes Diet

10%

Healthy Diet

10%

Table 4.6: The usual eating behaviour described by cardiac transplant
recipients

Exercise
Participants described exercise habits in terms of frequency, intensity and type of activity.
At 12 to 24 months post-transplant, only 48 per cent of cardiac transplant recipients were
exercising at the recommended level of 30 minutes duration, three times per week. The
remaining participants were either exercising at a level below this or were sedentary.

Appetite

To determine possible factors which may mfluence dietary intake, participants were asked
to rate their current appetite and any changes in appetite since transplantation. The
majority of participants reported that their current appetite was excellent and that appetite
had increased following transplantation These results are described in Table 4.7 and 4.8.

Current Appetite

Per cent

Poor

4%

Good

37%

ExceUent

59%

Table 4.7: Appetite at 12 - 24 months post-transplant
as described by cardiac transplant recipients

Appetite

Changes

Per cent

Increased

81%

Decreased

11%

No Change

8%

Table 4.8: Self reported changes in appetite following
cardiac transplantation

5. DISCUSSION
Heart transplant recipients are faced with CAD as an ironic impediment to long term
survival. Conventional cardiovascular risk factors potentially contribute to this disorder.
This study was initiated to describe the cardiovascular profile of a healthy post-cardiac
transplant population. Dietary intake was investigated to further describe cardiovascular
risk and identify adherence with current nutritional recommendations.

5.1 Lipid Levels
Previous studies have demonstrated that elevations in plasma lipids occur frequently
following cardiac transplantation and that these are strongly related to CAD development
(Winters et al 1990; Barbir et al 1991; Eich et al 1991). In the present study, 41 per cent
of transplant recipients displayed hyperlipidaemia at twelve months post-transplant, as
evident by the administration of lipid lowering drugs or cholesterol / triglyceride levels
above desirable ranges. The prevalence of lipid abnormalities in this study is lower than
that suggested by other researchers. Rudas et al (1990) for example, reported that 83 per
cent of cardiac transplant recipients manifested hypercholesterolaemia by one year posttransplant. Similarly, Keogh et al (1988) found that 50 per cent of transplant recipients
with underlying ischaemic heart disease and 33 per cent of those with diagnosed nonischaemic cardiomyopathy displayed cholesterol elevations beyond desirable levels.
These inconsistencies can be attributed to several key differences in the research. Firstly,
differing definitions of lipid elevations have been used by investigators. Rudas et al
(1990) for example, used total cholesterol levels >5.2 mmol/ L to describe lipid
elevations.

Whilst Keogh et al (1988) considered a significant degree of

hypercholesterolaemia to be total cholesterol >6.5 mmol/L.

In this study,

hyperlipidaemia was described as total cholesterol greater than 5.5 mmol/L or
triglycerides >1.8 mmol/L. As a result of these varying definitions, the prevalence rates
show obvious differences. In addition, differences in medication protocols between

study populations (particularly lipid lowering agents), differences in sample sizes and the
timing of post-transplant blood lipid measurements are likely to influence results.

The prevalence of lipid abnormalities in this group is comparable to those found in the
general population. The National Heart Foundation Risk Factor Prevalence Survey
(1989) demonstrated that 47 per cent of males and 39 per cent of females had cholesterol
levels exceeding 5.5 mmol/L. Whilst 17 per cent of males and 7 per cent of females had
triglyceride concentrations of greater than 2.0 mmol/L. On the surface this may suggest
that the cardiac transplant population are in fact no different from the Australian
population in terms of this cardiovascular risk factor. However, considering the
accelerated rate at which CAD often appears in transplant recipients and a primary
background of cardiovascular complications, these patients are possibly at greater
cardiovascular risk due to lipid elevations than the general population. Hence, cholesterol
levels above desirable should be treated aggressively in the post-transplant period.

The pattern of lipid abnormalities demonstrated in this study suggests that
hyperlipidaemia develops immediately following cardiac transplantation.

The

development of serum cholesterol elevations occurred within the first three months posttransplant. After this time and up to twelve months post-transplant, cholesterol levels
remained at the currently recommended levels or slightly elevated. Other studies have
demonstrated a similar time course for hypercholesterolemia. Both Stamler et al (1988)
and Rudas et al (1990) found that total cholesterol elevations reached statistical
significance at three months post-transplantation. After this time, some investigators
have found that blood lipids continue to increase (Ballantyne et al 1987), whilst others,
like that found in this study, have demonstrated that these biochemical indicators remain
elevated throughout the post-transplant period without further significant increases
(Becker et al 1988; Stamler et al 1988).

Serial evaluations of triglyceride levels in this study showed a similar pattern of posttransplant elevation. Inconsistencies in the availability of data however, did not allow for
statistical analyses. Despite this, a trend towards triglyceride elevations was evident from
three months following transplantation, suggesting that this population show some
characteristics of hypertriglyceridaemia. Other studies have confirmed that this lipid
abnormality is evident following cardiac transplantation (Becker et al 1987; Keogh et al
1988). However, in the present study, a high prevalence of hypertriglyceridaemia may
not have been evident because of the small sample size, missing data and the selection of
patients with normal liver and renal function.

Although lipid elevations were determined to be significant at three months posttransplant, it is important to recognise that in the present study, pre-transplant blood lipid
levels were analysed at end-stage cardiac failure. Hence, blood lipids may have been
artificially depressed by myocardial infarction, cardiac cachexia, elevated catecholamines
and changes in gastrointestinal absorption, even in patients with known pre-transplant
hyperlipidaemia and ischaemic heart disease (Ballantyne et al 1987). Pre-morbid lipid
values would therefore provide a more valid comparison of pre versus post-transplant
lipid elevations. Despite this, it is still notable that the mean three month post-operative
cholesterol level of 6.1 ± 1.6 mmol/L is above the recommended range for total
cholesterol, indicating that hypercholesterolaemia is an issue for the heart transplant
population immediately post-transplant.

Data on changes in lipoprotein cholesterol following cardiac transplantation were not
available for analysis in this study.

Other researchers have demonstrated that the

lipoprotein profile of this population tends to be particulariy atherogenic. Stamler et al
(1988) demonstrated that LDL cholesterol elevations were evident from two weeks
following cardiac transplantation. The total cholesterol to HDL cholesterol ratio which
correlates with cardiovascular risk was also found to increase throughout the first posttransplant year. Other researchers have also reported transient increases in HDL

cholesterol levels, however, these appear to stabilise within the first three months posttransplant (Becker et al 1988; Ballantyne et al 1992). Although cholesterol sub-fractions
were not reported in the present study, it is likely that the pattern of lipoprotein changes
demonstrated by other researchers was similar for this population.

The development of hyperlipidaemia in this population could be the result of a number of
factors. Other researchers have shown that obesity is strongly associated with lipid
elevations (Keogh et al 1988; Rudas et al 1990). Considering the high prevalence of
overweight and obesity in this population, this is a potential contributing factor. The use
of immunosuppressive medications may have played a role in this disorder, as all
participants were receiving triple drug immunosuppression with cyclosporine,
azathioprine and prednisone. Prednisone alone has been shown to elevate cholesterol and
triglyceride levels by up to 10 and 20 per cent respectively (Bagdale et al 1970). The
establishment of low maintenance doses of immunosuppressants may also explain the
stabilisation of lipid values seen up to 12 months post-transplant. The administration of
anti-hypertensive medications which in renal transplant patients has been associated with
hyperlipidaemia (Vathsala et al 1989) was also frequent in this population. It is also
possible that diet contributed to hyperlipidaemia, as the dietary intakes of fat and samrated
fat were greater than desirable in a considerable proportion of patients. This is strongly
associated with total cholesterol elevations (Kromhout et al 1989). In addition, physical
activity, which has benefits for lipid profile including reductions in LDL cholesterol, was
generally low for this population.

Overall, the results of this study suggest that hyperlipidaemia is a cardiovascular risk
factor which develops in a considerable proportion of transplant recipients following
cardiac transplantation. It appears that this anomaly is particulariy a problem during the
first three months post-transplant. Considering the predisposition to cardiovascular
problems in this population and the negative implications of hyperlipidaemia for CAD
development, close monitoring and tight control of blood lipid levels through

pharmacological, dietary or lifestyle intervention may be beneficial to the cardiovascular
health of this population.

5.2 Body Weight
Weight gain following cardiac transplantation has the potential to influence the
establishment of other cardiovascular risk factors and possibly influence CAD
development. The prevalence of overweight (BMI >25) in this population was 56 per
cent at 12 months following transplantation. At the same time, one third of these patients
were classified as obese (BMI >30). The findings of Grady and Herold (1988) suggest
similar prevalence rates, with 51 per cent of transplant patients in their study population
being overweight at six months following transplantation. This compares with more
recent studies on post-transplant obesity by Lake et al (1993) who reported a 39 per cent
prevalence of overweight at 12 months post-transplant, suggesting that weight gain
appears to more widespread in the present study population. This variance may be due to
an actual difference in weight gain in this study population or possibly be the result of
difference in sample size or classifications of overweight and obesity.

The temporal sequence of body weight changes in this study was an initial decrease in
mean BMI from 24.7 pre-transplant to 23.9 (p<0.01) at one month post-transplant. This
immediate post-transplant weight loss could be attributed to an acute post-surgical phase,
infection or early rejection (Kumar and Coulston 1983). Alternatively, it is possible that
significant decreases in mean weight did not actually occur, as pre-transplant weights
were recorded at initial assessment for cardiac transplantation, often several months
before transplant procedures. As a result, patients may have weighed less immediate pretransplant and at one month may have had similar body weights. Because cardiac
transplantation is an emergency procedure and reliant on the availability of donor hearts,
data on pre-transplant body weight at a comparable points in time for each recipient is not
obtainable.

Following immediate post-transplant weight loss, body weight increased progressively
up to 12 months post-transplant with significant gains between each increment (p<0.01).
The mean weight gain at 12 months from baseline was 7.8 kilograms in this study
population.

These findings are comparable to those reported by several other

researchers.

Grady and Herold (1988) demonstrated a mean weight gain of 7.4

kilograms at six months post-transplant. Further changes in weight were not reported
after this time. Hagan et al (1990) reported a slightly higher increase of 8.7 kilograms at
one year in transplant patients maintained on corticosteroid therapy. In comparison,
Keogh (1988) who undertook a previous study on the St. Vincent's Hospital transplant
population reported a mean weight gain of 4 kilograms at 12 months after cardiac
transplantation. The findings of a mean 12 month weight gain of 7.8 kilograms in the
present study suggest that Keogh's recommendations for more stringent efforts at weight
control have not been adequately implemented. In addition to this, patients selfassessments of their own body weight suggests that weight not only returns to premorbid levels, but in a large number of transplant recipients, actually exceeds pretransplant usual weight. As a result, the degree of weight gain in this group of patients
may not only be unacceptable in terms of reference standards, but also exceed the patients
own previously set-point for body weight.

Although these findings suggest that body weight increases over time following cardiac
transplantation, several factors which affect the accuracy of these results must be
considered. Firstly, information regarding body weight was obtained from St. Vincent's
Hospital medical records and not measured directly by the researcher. As a result,
measurements were taken by a number of hospital staff and to differing degrees of
precision (eg. 1.0 kg versus 0.25 kg). Also, height was obtained from pre-transplant
records and although this was verbally confirmed with participants, it is not known if
transplant patients were actually measured to obtain this data. In addition, the presence of
oedema in this population, which occurs as a result of prednisone therapy may have
potentially influenced any measures of body weight in this study. Finally, participants

self-assessment of changes in body weight following transplantation may have been
skewed by the fact that many were ill for a long period prior to the availability of a
suitable donor heart. As a result, usual or healthy body weight may have been underestimated.

Evidence suggests that the distribution of body fat is predictive of cardiovascular risk in
the non-transplant population (Donahue et al 1987; Ducimetiere and Richard 1989; Hartz
et al 1990). Although this has yet to be investigated in cardiac transplant recipients, it is
likely that the presence of abdominal or android obesity has similar metabolic and
cardiovascular complications for this population. Prior studies on the body composition
of cardiac transplant patients have suggested that percentage body fat is increased and
muscle mass is reduced (Ketayian et al 1992). However, the pattern of fat distribution in
this population remains largely undescribed. One previous study undertaken with renal
transplant recipients suggested that fat redistribution, as associated with
immunosuppressive therapy in transplant patients was not evident (Horber et al 1986).
In comparison to this, the findings of the present study which utilised the WHR and
waist circumference suggested that an abdominal pattern of fat distribution was frequent
in the post-transplant population. Eighty eight per cent of transplant recipients had WHR
greater than recommended, whilst 33 per cent had a waist circumference in excess of 100
centimetres.

These indices suggest that abdominal obesity poses considerable

cardiovascular risk to the transplant population.

The limitations of the chosen methodology, however must be considered before making
any conclusions regarding the body fat distribution of the transplant population. Other
researchers have suggested that WHR may not be predictive of cardiovascular risk in
individuals with a small hip circumference (Despres et al 1990). Measurements of the
WHR also fail to distinguish visceral metabolically active fat from subcutaneous
abdominal fat (Ross et al 1992). Whilst, in obese patients, difficulties in identifying
measurements sites reduce the accuracy of the results. Further research into body fat

distribution utilising other assessment techniques may provide more insight into the
cardiovascular profile of this population.

When compared to measures of overweight and obesity in the Australian population, the
post-cardiac transplant population display a tendency towards higher mean body weights
and waist circumferences. The mean BMI of men and women reported by the National
Heart Foundation (1989) was 25.3 and 24.3 respectively. In comparison, the mean 12
month post-transplant BMI in this population was high at 27.1. Additionally, the average
waist circumference of 100.7 cm demonstrated in this study is considerably greater than
the 89 cm for men and 76 cm for women reported by the National Heart Foundation.
This evidence suggests that the transplant population may be at increased cardiovascular
risk in regards to body weight than the general population.

The cause of post-transplant weight gain in this population is most likely multi-factorial.
Steroid administration however, appears to play a significant role. Other researchers
have demonstrated that transplant recipients maintained on steroids, gain significantly
more weight than those undertaking corticosteroid free maintenance therapy (Hagan et al
1990). The mechanism for this effect has been laigely related to steroid induced appetite
changes. In this study, 59 per cent of recipients reported that their present appetite (at 12
to 24 months post-transplant) was excellent, while only 4 per cent suggested that appetite
was poor. Poor appetite seemed to appear in patients who were ill at the time of the study
or taking appetite altering medications. The majority of post-transplant recipients (81 per
cent) also reported that their appetite had increased over the post-transplant period. As a
result of altered appetite patients may exhibit energy intake in excess of physiological
requirements, of which weight gain is the result. In addition to the adverse effects on
appetite, steroids have also been shown to stimulate changes in body composition
(Schneider et al 1977). Increased truncal or abdominal fat tends to be the result. Steroid
administration in the present patients population may therefore also act to explain the high
prevalence of abdominal obesity.

A history of pre-transplant obesity has also been suggested to predict the development of
overweight and obesity following cardiac transplantation ( Hagan et al 1990; Lake et al
1993). The present study confirmed this. At 12 months post-transplant, nine of the
participants in this study were obese (BMI >30). Retrospective analysis of weight
records revealed that all of these patients were actually overweight (BMI >25) prior to
transplantation. As a result, close monitoring of patients displaying a pre-transplant
weight above desirable or with a history of overweight may assist in reducing the
prevalence of this long-term complication of cardiac transplantation.

Physical inactivity may also enhance weight gain in this population. Over a half of the
transplant population were either exercising below the currently recommended 30
minutes, three times per week or sedentary in their activity level. The combined effect of
corticosteroids and physical inactivity, superimposed on a history of obesity may
therefore contribute to the increased body weight seen in this group of patients following
cardiac transplantation.

The adverse implications of excessive weight gain in the transplant population are
multiple. Overweight and obesity have been associated with elevations in total
cholesterol, LDL cholesterol, triglycerides and reduced HDL cholesterol levels (Bonora et
al 1991).

Several studies have confirmed that weight gain is a key factor in lipid

elevations in transplant recipients (Keogh et al 1988). The development of posttransplant diabetes mellitus may also be related to some extent to weight changes (Hagan
et al 1990), although has not been adequately investigated in this population, to date.
Furthermore, inappropriate weight gain has been shown to exacerbate hypertension and
adversely affect cardiac functioning, which in the long term may have deleterious effects
on the integrity of the transplanted heart (Hagan et al 1990).

Although weight gain is a concern for the cardiovascular health of the majority of
transplant recipients, in a small number of patients weight gain in the post-transplant

period may actually be beneficial. At one month post-transplant, five transplant recipients
were below the healthy weight range as indicated by a BMI <20. Increases in weight,
particularly fat free mass to achieve a weight appropriate to height, is therefore desirable
for this sub-group of transplant recipients.

The present study provides considerable evidence that body weight increases over time
following cardiac transplantation. In general, this group of patients are inclined to be
overweight with an android pattern of fat distribution, which indicates that they have a
high risk profile for CAD development. Measures to alleviate this clinical problem would
therefore be beneficial. It is possible that aggressive cardiac rehabilitation, pre-transplant
weight reduction (in obese patients) and patient education may be a means of addressing
the weight control issue. Whilst there is some evidence that behavioural techniques may
achieve sustained weight reduction in this population (Robert et al 1990). Ultimately, the
most appropriate intervention for attaining and maintaining a healthy body weight would
be individualised, implemented early post-transplant and take into account the myriad of
factors which impact upon the weight status of cardiac transplant recipients.

5.3 Diabetes Mellitus
Post-transplant diabetes mellitus is a significant long-term complication of cardiac
transplantation. The prevalence of this disorder has been reported to vary from 8 to 14
per cent depending on the definition used (Utresky et al 1987; Ladowski et al 1989). In
the present study, a total of seven post-cardiac transplant patients displayed diabetes in
the post-transplant period. Of these, two had diabetes prior to transplantation and the
remaining five developed this complication in the post-transplant period. The resultant
prevalence of post-transplant diabetes mellitus was therefore 19 per cent. Of these
patients, two were maintained on insulin and the remaining five on oral hypoglycaemic
agents.

In the patient population studied for this research, blood glucose levels were not regularly
available for analysis. Detection of diabetes mellitus in this population therefore tended to
occur symptomatically, rather than early in the post-transplant period. It is plausible
therefore, that a considerable proportion of these patients have undiagnosed diabetes
mellitus. As a result, the actual prevalence rates for diabetes following cardiac
transplantation would be much higher. The irregular blood glucose monitoring of these
patients also failed to allow for any analysis of diabetic control or detection of the
temporal sequence of diabetes development in this population.

The underlying cause of diabetes mellitus in this population is likely to be the combined
effect of immunosuppressive administration and post-transplant weight gain. Steroids
are thought to induce diabetes via the effects on peripheral insuHn resistance and impaired
glucose tolerance (Gardiner 1993). Cyclosporine on the other hand has been linked to
similar metabolic changes, however this has yet to be demonstrated in this patient
population. In this study, all transplant recipients were receiving both corticosteroids and
cyclosporine. Weight gain, as common in this population, also corresponds to the
development of insulin resistance and in the long term, decompensation of pancreatic
function (Thomas 1994). As a result diabetes may have developed in a number of these
patients as a result of inappropriate weight gain over the post-transplant period.

In the present study, it was difficult to make any valid conclusions regarding posttransplant diabetes mellitus, because of the limited amount of available data. Despite this,
it is evident that the presence of diabetes mellitus in this population is likely to have
negative implications for cardiovascular profile. As a result, early diagnosis, weight
control and appropriate dietary intervention would be beneficia! to this patient population.

5.4 Blood Pressure
Hypertension is a significant complication of cardiac transplantation that has been
reported to affect up to 90 per cent of all post-transplant recipients (Radovancevic et al
1990; Renuld et al 1989).

Although blood pressure elevations have not been

unequivocally linked to post-transplant CAD, there is some evidence that this may be a
contributing risk factor to the development of this disorder (Winters et al 1990;
Radovancevic et al 1990). In this study, hypertension as defined by a diastolic blood
pressure >95 mmHg or the administration of anti-hypertensive medications, was evident
in 73 per cent of long-term transplant recipients. It is possible that the prevalence in this
study was actually lower than that reported by other researchers because of the small
sample size, the exclusion of patients with diagnosed renal impairment or the definition of
hypertension used.

Over time the development of hypertension tended to become more prevalent.
Immediately post-transplant only 52 per cent of transplant recipients displayed this
disorder. By six months post-transplant the prevalence of hypertension reached 67 per
cent and by 12 months 73 per cent of this population were hypertensive. Although
hypertension appears to be a frequent complication of transplantation, blood pressure was
generally maintained within recommended limits in this group of patients. The mean
diastolic blood pressure at 12 months post-transplant was 84 mmHg, whilst systolic
blood pressure averaged at 134 mmHg. In the present study, none of the transplant
recipients displayed persistent uncontrolled hypertension. It is likely that this is the result
of close monitoring and pharmacological intervention in the post-transplant period.
Although it is plausible that these results reflect the fact that blood pressure was measured
only once at each point in time. Since the requirements for a diagnosis of hypertension
require blood pressure elevations from consecutive readings, it is possible that blood
pressure control or the prevalence of hypertension therefore, actually differed from these
findings. However, in theory, if blood pressure is as well controlled as indicated by this

study, complications for cardiac function and CAD development are likely to be
minimised.

In comparison to data from the Australian population, evidence from this study suggests
that transplant recipients are considerable different from the general population in regards
to the development of this disorder. Population studies, using the same blood pressure
classifications as used in the present study, suggest that hypertension is present in 17 per
cent of men and 13 per cent of women (National Heart Foundation 1989). The 73 per
cent prevalence rate for hypertension in this study therefore indicates that other factors
clearly play a role in this disorder. Despite this, the degree of blood pressure control was
relatively similar to population levels.

The underlying cause of hypertension in cardiac transplant patients has been most
strongly related to cyclosporine administration (Myers et al 1984; Martin et al 1987). In
this study, all patients were receiving immunosuppression with this medication over the
post-transplant period, suggesting it as a probable underlying factor. However, the
frequent development of blood pressure elevations in the pre-cyclosporine era of cardiac
transplantation has suggested that other factors may contribute to this disorder (Ozdogan
et al 1990). It is possible that blood pressure increased in response to post-transplant
induced physiological changes (Shapiro et al 1990). This could not be examined in this
study. Prednisone has also been implied as a causative factor. However in the present
study, the prevalence of hypertension increased over time, whilst steroid administration
was reduced. Hence this relationship is unlikely. Alternatively, weight gain which
correspondingly increased over time with elevations in blood pressure may act to explain
the prevalence of this disorder. This hypothesis is supported by evidence from nontransplant populations which has strongly linked weight gain to elevations in blood
pressure (Havlik et al 1983).

Although blood pressure was on the whole, well controlled in this population, it could be
hypothesised that a combination of weight reduction, sodium restriction and lifestyle
modifications (eg. smoking cessation, physical activity) may alleviate the need for
pharmacological treatment of this disorder. Although this has been demonstrated to be
the case in the general population (Elmer et al 1991), few intervention studies including
heart transplant recipients have been reported to date. However, until these studies
provide more of an insight into possible treatment alternatives for this disorder, frequent
monitoring and control of blood pressure, as is currently being implemented, should
continue for these patients.

Whilst non-pharmacological interventions should be

encouraged as a complementary CAD preventative measure.

5.5 Dietary Intake
The goal of long-term nutritional therapy for the heart transplant recipient includes
achieving reductions in total fat, saturated fat, cholesterol, alcohol and sodium, whilst
increasing intakes of carbohydrate and dietary fibre (Frazier et al 1985). Although the
efficacy of such a healthy heart diet in improving the cardiovascular profile of cardiac
transplant recipients has not been widely reported, evidence from some researchers
suggests that dietary modifications may positively influence blood lipids, blood pressure
and body weight (Salen et al 1994; Singer et al 1994). In the present study, the intake of
each of these dietary components was analysed for all participants using an extensive diet
history.

Fat intake is one dietary component which has implications for plasma lipids, lipoproteins
and body weight. As a result, a high fat diet has been associated with an increased risk
of cardiovascular diseases (Shrapnel et al 1992). In the present study, the fat intake of
long-term cardiac transplant recipients contributed a mean 31.7 per cent of energy to the
diet. This was significantly higher than the recommended <30 per cent of energy
(p<0.05), however less than the average intake reported for the Australian population
(Lester 1994).

Thirty seven per cent of transplant recipients met the current

recommendations for total fat intake and 26 per cent actually had a fat intake >35 per cent
of energy. It is interesting to note however, that 51 per cent of transplant recipients
indicated that they were following a diet which included reductions in total fat content.
This suggests possible inaccuracies in dietary analysis or discrepancies between
participants perceptions of what constitutes reductions in dietary fat and an actual low fat
diet.

Consequently, recommendations for reducing total fat intake and the means by

which this can be achieved should be reinforced in the cardiac transplant population.

The saturated fat intake of this population was also significantly higher than current
recommendations (p<0.05). The mean intake of saturated fat 11.1 per cent of energy,
whilst that which is recommended is less than 10 per cent of energy. Only one third of
transplant recipients were currently consuming a saturated fat intake as desired.
Reducing the saturated fat content of the diets of transplant recipients is therefore
recommended. Salen et al (1994) provided evidence that such a dietary modification may
be advantageous for the cardiovascular profile of this population, reducing both total
cholesterol and LDL cholesterol levels.

The cholesterol intake of this group of patients was also assessed in the present study.
The mean cholesterol intake of 317 milligrams per day did not differ significantly from
the maximum 300 milligrams per day as desired. Most participants in this study had low
to moderate cholesterol intakes with only a small group of recipients greatiy exceeding
recommendations. Overall, this suggests that transplant recipients generally adhere to
low cholesterol dietary recommendations which may be beneficial to cardiovascular
profile.

Alcohol is considered to pose cardiovascular risk at high levels of consumption (Ahlawat
and Siwach 1994). In this study, 37 per cent of cardiac transplant patients were nondrinkers. The remaining 63 per cent reported low alcohol intake. Hence cardiovascular
risk in terms of frequency and quantity of alcohol consumed was low for this population.

In heart transplant recipients sodium restriction is recommended for blood pressure
control and to eliminate the presence of oedema caused by steroid administration (Kumar
and Coulston 1983). Previous studies on the cardiac transplant population have shown
that blood pressure is sensitive to reduced sodium intake and that extremely low sodium
diets can result in large decreases in systolic blood pressure (Singer et al 1994).
Extrapolating these results, it is possible that a sodium intake at the recommended level of
40 to 100 mmol per day can achieve modest blood pressure reductions. In this study,
dietary analysis revealed that the mean sodium intake of this population was 121.9 mmol
per day and that 71 per cent of transplant recipients had sodium intakes greater than
recommended. It was also interesting to note that only a small proportion of transplant
recipients actually reported the addition of salt to their diets, suggesting that sodium
intake was obtained from other dietary sources. Hence, there is room for dietary
intervention to reduce the sodium intake of this group of patients.

An adjunct to the recommended low fat intakes for a healthy heart diet is an increase in
carbohydrate and dietary fibre intake. The style of eating has been shown in general
population studies to be beneficial for cardiovascular profile (Schaefer et al 1981;
Anderson et al 1991). In the present study, carbohydrate intake as a percentage of energy
was low at a mean 41.5 per cent. This was significantly less than the recommended 55 to
60 per cent contribution to energy (p<0.01). Total daily fibre intake on the other hand
was high and met the desired intake of 25 to 30 grams daily. This unusual dietary pattern
is possibly the result of a high total energy intake, which may explain the high fibre yet
low percentage energy contribution from carbohydrates. It could be assumed therefore,
that a considerable proportion of transplant recipients were following dietary
recommendations for increasing fibre intake.

Overall, the results of this analysis suggest that the diets of a considerable proportion of
transplant recipients exceed current recommendations for total fat, saturated fat and
sodium. Dietary fibre intake tends to be high, whilst carbohydrate and alcohol intakes are

on the whole, low. Before making any conclusions regarding the adherence with healthy
heart recommendations in this population, however, the limitations of the chosen dietary
assessment methodology must be considered. The diet history, like other techniques has
several limitations in dietary assessment. Although it provides a good indication of usual
intake it may neglect infrequently consumed food, inaccurately estimate or over-report
intake (Thompson and Byers 1994). Thus any results must be interpreted with care.

Although the underlying aetiology of post-transplant CAD is not necessarily diet related
and the role of dietary intervention has yet to be proven in improving the cardiovascular
profile of cardiac transplant recipients, promoting a diet which corresponds with a healthy
heart pattern of eating is a safe means of promoting sound nutritional health whilst
possibly achieving cardiovascular benefits. Although the diets of the heart transplant
population more comparable with healthy heart guidelines than intakes reported in the
general population, considering the predisposition to cardiovascular complications in
transplant recipients, adherence with recommendations is vital. Thus cardiac transplant
recipients who presently only receive immediate post-transplant dietary intervention may
benefit from appropriate nutrition education and counselling extending beyond the initial
post-transplant period.

6. CONCLUSION

The findings of this study suggest that the St. Vincent's Hospital heart transplant
population have a high risk profile for the development of cardiovascular complications
including post-transplant CAD. Although the development of these risk factors appears
highly related to the metabolic consequences of immunosuppressive therapy and other
factors unique to transplant recipients, there is some evidence that these risk factors are
modifiable with appropriate preventative and treatment protocols.
Hyperlipidaemia was a post-transplant cardiovascular risk factor which developed in this
study population. At three months post-transplant, total blood cholesterol increased
significantly from pre-transplant values and by 12 months post-transplant, 41 per cent of
recipients were hyperlipidaemic. Although the prevalence and degree of this disorder
was less than previously reported by other researchers, the combined effect of lipid
elevations with immunological factors has the potential to influence CAD development.
Overweight was possibly the most significant cardiovascular risk factor evident in the
post-cardiac transplant population. Immediately following transplantation, body weight
decreased in these patients. Ensuing this, weight increased progressively over time and
significant gains were apparent at measurement interval. Measures of body fat
distribution indicated a disposition towards abdominal obesity. Corresponding increases
in appetite and low levels of physical activity were demonstrated in this population.
Consequently, obesity may be significant not only in its independent effects on
cardiovascular health but via its influence on the establishment of other risk factors
including hypertension, diabetes mellitus and hyperlipidaemia. Thus it is possible that
ameriolation of weight gain may be one of the most important CAD preventative
measures.

Diabetes mellitus was also evident in a small number of transplant recipients. The
prevalence for this disorder being 19 per cent at 12 months post-transplant. However, it
is possible that because of the presently inadequate blood glucose monitoring of these
patients the prevalence of diabetes mellitus is much higher. It is likely that the combined
effect of steroids and weight gain contributed to this disorder which has negative
implications for cardiovascular profile.

Hypertension was one of the most prevalent of all cardiovascular risk factors in this
population affecting 73 per cent of transplant recipients. Analysis of blood pressure
measurements however indicated that this disorder was well controlled in the transplant
population. Hence the cardiovascular risk posed by this disorder is minimised.

Comparison of the usual dietary intake of the cardiac transplant population with current
healthy heart recommendations suggests that long-term adherence to dietary advice is
sub-optimal in a considerable proportion of transplant recipients. Intakes of fat, saturated
fat and sodium were generally greater than recommended, whilst carbohydrate intake was
lower than desirable. Alcohol and cholesterol intakes on the other hand were within
currently recommended levels.

Overall, the evidence from this study suggests that the potential exists for improving the
cardiovascular profile of long-term cardiac transplant recipients. With monitoring and
appropriate intervention it is hypothesised that the development of CAD in this population
could be delayed or even reduced. However, further studies incorporating larger samples
of transplant recipients are required to substantiate this.

7. RECOMMENDATIONS
On the basis of the findings of this study it is recommended that:

1. Blood lipid levels including both triglycerides and total cholesterol be regularly
monitored in the post-transplant period. Transplant recipients who display undesirable
lipid profiles which compromise cardiovascular health should be targeted for appropriate
pharmacological, dietary or lifestyle intervention.

Information regarding lipid

subfractions, particularly LDL nad HDL cholesterol would also be beneficial in patient
monitoring, however the cost effectiveness of such an approach needs to be considered.

2. Weight gain in post-cardiac transplant patients be monitored at regular intervals and
appropriate interventions implemented. A multi-disciplinary approach to the weight
control issue should be encouraged. Medical and nursing staff who have regular contact
with transplant recipients should identify inappropriate weight gain and target patients for
intervention. Ideally, this would include referral to a clinical nutritionist and other allied
health staff who are involved with lifestyle intervention (eg. physiotherapist,
psychologist). The most appropriate intervention would consider all factors relevant to
post-transplant weight gain (eg. appetite, quality of life, physical activity) and be
individualised to meet the patients requirements. Group education may also be effective
as the group dynamics for this small population of patients is likely to be positive.

3. Waist-to-hip ratio be routinely measured as an assessment of cardiovascular risk. This
would be particularly important in this population who are susceptible to increased central
or android adiposity as a consequence of steroid administration. In such routine
measurements, standard sites and acceptable cut-off ratios should be pre-determined.

4. Blood glucose levels be monitored at regular intervals following cardiac
transplantation. This would allow for early identification of diabetes mellitus and suitable
medical and nutritional intervention. In turn, this may act to delay the progression of
complications (including CAD) through the establishment of good blood glucose control.

5. Blood pressure continue to be monitored to the present level and interventions to
control hypertension implemented m the early post-transplant period.

6. Transplant recipients receive long term dietary follow-up from a clinical nutritionist.
Healthy heart dietary guidelines should be reinforced with the aim of achieving acceptable
lipid, weight and blood pressure profiles. The most effective intervention should
incorporate practical aspects of improving dietary intake and focus on what foods are
appropriate for consumption rather that those which are not.

7. Exercise be encouraged in this population both for cardiovascular benefits and weight
control. This should include the currently recommended minimum of 30 minutes at least
three times per week.

8. LIMITATIONS
The present study was limited by:

1. Small sample size
Due to time and resource constraints, only 27 cardiac transplant recipients could be
included in the present study. Had a larger sample size been included, the significance
these findings may have been stronger.

2. Missing Data
As information was obtained from pre-existing medical records, data collection was
limited by information not recorded in medical records. This was particularly the case
with blood lipid analysis.

3. Dietary intake methodology
The diet history method used to collect dietary intake data in this study is subject to
inaccuracies, related to the large subjective component of this method, the reliance on
participant memory and the degree of estimation involved with this technique. As a
result, this dietary information gathered in this study may have been subject to over or
underestimation.

4. Accuracy of retrospective data
Body weight was measured by a variety of different hospital staff and to differing
degrees of precision. As a result, measurements of weight in the present study are
subject to potential inaccuracies.

For a diagnosis of hypertension, blood pressure elevations are required over three
consecutive readings. However, because blood pressure was retrospectively analysed

from medical records only one reading for each time period was available in this study.
Hence, the actual blood pressure of participants may have differed from recorded
readings.

5. Failure to examine all cardiovascular risk factors
Other cardiovascular risk factors (eg. smoking) were not examined in the present study.
Hence the existence of multiple risk factors could not be adequately determined in this
study.

9. AREAS FOR FURTHER INVESTIGATION:
Since heart transplantation is a relatively new procedure and the long-term complications
are only just being recognised, there are at present many areas for investigation which
have yet to be fully examined in the literature. These include:

1. The effectiveness of dietary intervention in preventing cardiovascular
complications such as CAD. (eg. the effectiveness of a low fat diet in reducing
hyperlipidaemia, reducing sodium intake to control blood pressure etc.) A number of
studies have included diet as a component of the overall investigation however, to date,
large controlled studies in this area are absent. Such a study would provide evidence as
to whether more stringent healthy heart recommendations need to be developed for the
cardiac transplant population.

2. The most effective means of achieving sustained weight control in this
population. Excessive weight gain has multiple implications for the long term health of
transplant recipients. To date, there is little information regarding the most effective way
to alleviate this clinical problem.

3.

The

relationship

between

cardiovascular

risk

factors

and

the

development of CAD. Although this has been previously reported in the literature,
conclusions regarding the role of the different risk factors in the establishment of CAD
remains controversial. Further research is needed to elucidate contributing factors.

4. The prevalence of diabetes mellitus in this population, risk factors for
the development of this disorder and blood glucose control. To date in the
literature, little has been reported on post-transplant diabetes mellitus. This could not be
thoroughly examined in this study, due to infrequent monitoring of blood glucose levels.
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11.1 Project Approval Information

11.2 Letter to Cardiac Transplant Patients

9th August 1995
Dear
I am writing to ask you to take part in a study to help prevent long term health problems
in heart transplant patients. It is being conducted by Clinical Nutritionists at St.
Vincent's Hospital, in conjunction with a student from the University of Wollongong.
As a heart transplant recipient, the information that you provide could help us to
understand more about the incidence of heart disease and risk factors such as high
blood cholesterol, overweight and diabetes in heart transplant patients.
In turn, it may help to improve the nutrition services provided to heart transplant
patients such as yourself.
To gather this information, we are contacting a group of people who have received
heart transplants at St. Vincent's Hospital, Sydney. You are one of those people and
we would great;ly appreciate your help with this study which involves:
• Measuring your weight and height
• Measuring your waist and hips with a tape measure
• You telling us about your usual diet and appetite
• Obtaining information form St. Vincent's Hospital medical records about your
cholesterol levels, triglyceride levels, body weight and blood sugar levels
• Obtaining information regarding your age, medications and diagnosis from St.
Vincent's Hospital medical records
For us to collect this information, we will contact you to arrange an appointment here at
St. Vincent's Hospital or an alternative venue if more convenient. The appointment
will be for approximately one hour between August and October 1995.
If you agree to participate, your identity will not be revealed and all information will be
treated with the strictest confidence. If you decide not to take part or withdraw from the
study, this will in no way affect the services provided to you by St. Vincent's Hospital.

In the strong hope that you will participate, I will be contacting you by telephone with
the next few weeks.
In the mean time, if you have any questions or queries, feel free to contact Melinda
Morrison or Clare Rawcliffe at St. Vincent's Hospital on (02) 361 2552.
Thank you, in anticipation of your help.
Yours Sincerely

Melinda Morrison
Student
Department of Public Health and Nutrition
University of Wollongong

Clare Rawcliffe
Clinical Nutritionist
St. Vincent's Hospital

11.3 Standard Consent Form

CONSENT FORM
ST. VINCENT'S HOSPITAL /

UNIVERSITY OF WOLLONGONG

FORM FOR RESEARCH STUDIES

Project Title:
The cardiovascular profile and dietary intake of post-cardiac transplant patients
Investigators:
Di Cheah
BSc (Nutiition/Biology), MDAA, SRD (UK)
Deputy In Charge, Nutrition Services
St. Vincent's Hospital
Melinda Monison
BSc (Nutrition)
Student (Master of Science (Nutrition & Dietetics))
University of Wollongong
Clare Rawcliffe
Dip. Home Science, MDAA
Clinical Nutritionist, Cai'diopulmonai y Transplant Unit
St. Vincent's Hospital
Boris Gazibaiich
BSc, Grad. Dip Diet MCom
Lecturer and Academic Supervisor
University of Wollongong
Contact person:
Melinda Monison
(042) 94 1819
Di Cheah
(02) 361 2554

1.

You are invited to participate in the experiment described below which is
being conducted as a pai t of the Master of Science in Nutrition and Dietetics
degree at the University of Wollongong .

2.

Background to experiment
Heait disease is the most frequently observed long term complication of heart
tiansplantation. Risk factors for heart disease include obesity (particularly
abdominal), high blood pressure, high cholesterol and triglyceride levels and a
diet high in fat, salt and low in dietary fibre.
The aim of this study is to find out more about the occurrence of these risk
factors for heait disease in heait transplant recipients from St. Vincent's
Hospital, Sydney.
Forty heait transplant recipients from St. Vincent's Hospital have been
selected to paiticipate in this study. These participants must be over the age
of eighteen, have received a heart transplant within the past twelve to twentyfour months and have no other medical conditions (eg. cancer, kidney disease,
liver disease or pancreatic disease).
It is hoped that this study will assist the Department of Nutrition Services in
identifying aieas which require further dietary intervention.

3.

Description of Experiment - methods and demands
The study involves :
• Obtaining information from hospital medical records including: cholesterol
levels, triglyceride levels, body weight, initial diagnosis, sex, age and current
medications
• An interview to obtain inforaiation regarding your usual dietary intake
• Measuring body weight and height
• Taking waist and hip measurements using a tape measure
It is expected that the study will take approximately one hour.
All of the information obtained in this study will be recorded in writing and
stored at St. Vincent's Hospital. Only the researchers will have access to this
information and it will not be used for reasons other than those intended in

the reseai'ch. The data will be analysed and may be published in a medical or
nutrition journal. Paiticipants identities will not be revealed in any published
results.
4.

I acknowledge that I have read the above statement which explains
the nature and object and the possible risks of the investigation, and the
statement has been explained to me to my satisfaction. Before signing this
document I have been given the opportunity to ask questions relating to any
possible physical and mental harm I might suffer as a result of my
participation and I have received satisfactory answers. I have also been
informed that I may not receive any benefits from participating in this study.

5.

My decision whether or not to paiticipate will not prejudice my future
relations with St. Vincent's Hospital and the University of
Wollongong. If I decide to paiticipate, I am free to withdraw my consent and
to discontinue paiticipation at any time without prejudice.

6.

I agree that reseaich data gathered from the results of the study may
be published provided my name is not used.

DATE
7.

Signature of Patient or Authorised
Representative

I have fully explained to the patient
the nature
and purpose of the program and the procedures to be employed as
described above and such risks as ai'e involved in their performance.

DATE

Signature of Responsible
Investigator

8.

The foregoing is an accurate summary of the explanation which was made to
the patient/volunteer, and the undersigned witnessed the
signatures.
DATE

Signature of Auditor-Witness

NB. If you have enquires regaining the conduct of the research, please contact The
Secretary of the University of Wollongong Human Research Ethics Committee on

(042) 213079

11.4 Data Collection Sheets

DATA

COLLECTION

SHEET

Participant Identification No.:
Date:
Sex:
DOB:
Date Transplant:
Initial Diagnosis:
Medications:
• HT

• CHOL

• DM

Biochemistry:
Month T.Cho BSL's TG's
0
1

B.P.

|Wt.

1 BMI

3
6
12
18
24

1

1 1
1

1

Anthropometry
Weight (kg):
Waist (cm):
Hips (cm):
WHR:

#1:
#1:

Height (cm):
#2:
#2:

BMI:

FOOD FREQUENCY CHECKLIST
How many times each day / week would you eat the following foods:

/

Food
Bread
Breakfast Cereal
Pasta / Noodles
Rice
Fruit
Green Vege
Orange Vege
White Vege
Milk
Cheese
Yoghurt
Cream / Sour Cream
Eggs
Red Meat
Chicken
Fish
Processed Meats
Cakes
Biscuits
Chocolates
Confectionary
Nuts
Crisps / Snack Foods
Ice Cream
Soft Drinks
Cordials
Alcohol
Mayonnaise / sauces
/ gravies
Salt
Pepper

Daily

Weekly

Type

Food Preparation

Data

What kind of butter / margarine do you use?.
What kind of oil do you fry in?
What cuts of meat do you most commonly
use?
Do you eat the fat on meat?
How do you prepare your meat / fish /
chicken?
How do you prepare your vegetables?
What kinds of ready made / processed foods do you
eat?
Do you eat out or have take away's? How
often?
Have you seen a dietitian before?
Are you presently following any kind of special diet? If
yes, what kind?
How would you describe your appetite at present?
POOR
GOOD
EXCELLENT
Have you noticed any changes in your appetite since
your transplant?
INCREASED
DECREASED
NO CHANGE
Have you noticed any changes in your weight since your
transplant?
INCREASED
DECREASED
NO CHANGE
Do you participate in any regular exercise? If yes, what
and how often?

11.5 National Heart Foundation Standards
for Alcohol Risk

Risk Levels

Category

Description

A

Non-drinkers

B

Males

Females

Average intake less 3 drinks

None

Low

C

Average intake of 4 drinks or
9-12 drinks in any day

Low

Intermediate

D

Average intake of 5-8 drinks or
occasional excess

Intermediate

High

E

Average intake of 9-12 drinks
or frequent or great occasional
excess intake

High

Very High

F

Average daily intake over 12
drinks

Very High

Very High

Amount: No. of drinks

Frequency of Drinking

1-2

3-4

5-8

9-12

13-20

>20

Less than once week

B

B

B

C

D

E

1 or 2 days

B

B

B

C

D

E

3 or 4 days

B

B

C

D

E

F

5 or 6 days

B

C

D

E

F

F

Every day

B

C

D

E

F

F

11.6 Raw Data

MONTH
Pt.

Pre-op
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

3.4
5
4.8
3.9
5.6
4
4.6
5.2
7.5
4.8
3.4
3.8
2.9
2.3
5.9
5.1
6.3
3.5
3.7
4.8
5.6
3.4
6.4
3.1
2

1
7.9

4.9

5.9

5.3
3.2
7.5
6
5.7
5.6
7.2
6

11.8

3
5.4

5.5
5.6
5.9
8.9
5.8
6
5.2
4.4
5.8
4.2
7.4
6.7
6.2
6.1
4.4
10.6
5.4

6
5.6
7.3
6.8
5.54
6.5
5.5
4.7
6
7.7
6.6
6.1
5
4.3
5.2
4
6.7
5.5
5.3
7.2
4.7
3.9
7.8
5.8

8.1
5.3

12

18

24

5.1

6
4.7

4.8

5.3
5.3
4.7
6.3
6.2
5.8
6

5.4
3.9
6.9
5.6
4.4
6.5
4.7
4.5
6.6
5.5
5.7

5.2
6.3

1. Cholesterol Levels

4.8

6
3.5
6.8
5.9

4.7

6.2

5.9

6.9
4.3
5.8
5.7

4.9

MONTH
Pt.

Pre-op
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

1

12

18

24

2.8

2.2
2.5

2.3

0.9

0.9

1.7
3.9

1.3
1.2
3.4

1.16
1.9
2.73

1.41
1.9

2.8
1

4.1
1

2

2.7

1.5

1

1.8

2.26

2.5

2.6

1.6

1.5

1.6

1.4

1.7

2.2

1.02

1.1

1.2

1.5

3

6

1.1

2.88
3.8
0.97
0.89

0.7
3
1.3
0.7
1.4
1
1.4
2.5
3.5
1.7
1
1.1
1.2
2.08
0.7
1.5
1.3
1.5
2.9
3
0.9
1.2
1.2

1.1

1.1
1.7

2. Triglyceride Levels

1.7

1.46

MONTHS
Pt.

Pre-op
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

20
29
25
25
19
24
21
27
26
25
21
20
21
26
25
28
28
26
22
22
26
29
25
27
28
32
22

1
20
27
22
25
20
22
21
24
25
24
20
20
19
24
25
29
27
25
20
23
24
28
25
25
29
34
20

3
21
28
24
27
21
22
21
29
28
23
21
21
19
27
26
30
26
26
20
23
25
29
28
27
30
33
22

6
23
32
25
27
22
23
22
30
29
23
23
22
22
29
26
30
27
27
24
23
28
28
29
27
31
34
23

3. Body Mass Index

12
23
35
27
27
23
22
21
31
30
23
24
22
20
31
25
34
28
27
25
24
32
27
31
28
33
37
23

18

24

29
24
22
33
33

23

25

33

25

24

33

33

36
33
43
23

Energy
Kilojoules
Pt.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

8706.3
9636.3
7940.5
7801
11344.6
14260
13968
6724
7947.1
10526
7742
6892
12149.9
13273
14471.2
8152
10806
11247
15673
10640
7538
10780
9280
12685.5
7930.8
13229.7
10763.5

Total Fat
Grams
83.7
68.9
67.5
54.4
100.1
146.1
116.8
50.9
63
80.2
62.9
44.4
128.1
118
149.7
71.4
107.5
69
172.8
99.3
63.4
89.5
77.2
117.5
60.6
128.7
74.9

NUTRIENT
Saturated Fat Mono Fat
Grams
Grams
24.9
28.2
27.3
23.7
25.5
52.9
43.5
13.1
16.7
30.9
20.1
18.3
64.2
29.9
52.8
30
40.4
22.8
60.1
31.9
20.9
33.1
23.6
58.6
15.4
50.7
21.6

37,4
24.6
22.8
18.7
36.3
61.3
44.7
21
31.1
27.7
22
16.1
44.8
56.2
53.8
27.4
43.6
21.5
76.7
34.2
27.6
32.2
35
39.5
23.1
48
22.2

Poly Fat
Grams
10.5
8.8
11.7
lA
30.2
17.9
13.8
10.6
15.2
14.7
14.7
4.8
18.9
18.7
31.9
6.8
13.7
11.2
17.1
26.1
8.1
16.5
12.3
9
17.1
30
23

Protein
Grams
133.6
126.2
99
107.9
151.1
219.7
130.7
101.5
112.6
125.8
98.1
95
144
154.9
118.3
133.7
134.7
144.6
278.8
131.8
72.9
126
111
134.5
78.2
117
165.2

4. Nutrient Intakes

Carbohydrate Fibre
Grams
Grams
199.1
297
227.8
239.4

211A
330
409.2
127.4
208.8
273.4
219.8
213.1
291.5
287.3
406.6
151.3
210.2
373.3
259.9
228.6
185.3
319.5
220.3
347.7
258.8
297.1
299.1

31.7

iin

26.5
29.4
32.4
30.9
38
28.8
33.-7
21.3
21.9
21.5
29.8
56.1
29.1

21.1
24.3
63.8
31
19.7
30.8
33.2
20.8
32.3
35.7
220.1
54.5

Sodium
mmol
1185
150,6
85,5
188,2
113.1
132.8
158
70

\sin
111
140.5
95.1
132.8
142.2
214.9
61.8
84
117
72.6
140.7
83.2
122
112
11L9
71.1
113
134.2

Cholesterol
Milligrams
388.2
359
239
223.4
321.4
605.4
297
249.2
166.6
358
256
198.4
436.9
346.5
280
284.4
296.5
207
879
493.6
134.7
316
192.4
249.9
122.8
316
326.7

MALE
Pt
Mean Waist
Mean Hip
WHR
1
110
107
2
84.5
88
3
117
119
4
97
93
5
124.5
108
6
94
95
7
86
90
8
84
91
9
103
113
10
93.5
97
108
110
11
89.5
85
12
113
119
13
104
114
14
89
85
15
93
89
16
89
91.5
17
93
97.5
18
87
91
19
119
126.5
20
94
94
21
120
132.5
22
90
91.5
23
FEMALE
143.5
128
24
116
87
25
116
89
26
111
89
27

1.03
0.96
0.98
0.95
1.15
0.989
0.95
0.92
1.09
0.96
1.02
0.94
1.03
1.09
0.96
0.96
1.02
1.05
1.04
1.06
1
1.1
1.02
0.89
0.75
0.77
0.8

on
a
(U
(U
CO
cd
S
Oh
ffi
c/^
•S

